



Blood Drug Analysis Test No. 17-5661 Summary Report

This test was sent to 130 participants. The sample sets contained blood samples from three cases, each with an individual case scenario. Each case sample consisted of two grey-topped vials containing human blood with various drugs/metabolites. Participants were requested to examine these items and report their findings. Data were returned from 114 participants (88% response rate) and are compiled into the following tables:

| | <u>Page</u> |
|---|-------------|
| <u>Manufacturer's Information</u> | <u>2</u> |
| <u>Summary Comments</u> | <u>3</u> |
| <u>Table 1: Item 1 Results</u> | <u>4</u> |
| <u>Table 2: Item 2 Results</u> | <u>25</u> |
| <u>Table 3: Item 3 Results</u> | <u>64</u> |
| <u>Table 4: Additional Comments</u> | <u>89</u> |
| <u>Appendix: Data Sheet</u> | <u>90</u> |

This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

Manufacturer's Information

The sample sets contained blood samples from three cases, each with an individual case scenario. Each case sample consisted of two grey-topped vials containing human blood. Participants were asked to analyze the blood samples and report the presence of any drugs/metabolites and quantitative data obtained (including uncertainty).

SAMPLE PREPARATION-

The human blood used in this test was from the same lot, which tested negative for a variety of common controlled substances prior to being obtained from a commercial supplier.

A stock solution of each drug was used to spike the respective item. These solutions were obtained in sealed ampoules and were not opened until needed for production. Items were prepared at separate times using the following procedure, and different glassware was used for each item.

ITEMS 1, 2, and 3 (PREPARATION): Item preparation consisted of adding a predetermined amount of drug stock solution to human whole blood. It was stirred before pipetting the mixture into each of the pre-labeled vials, which contained Potassium Oxalate and Sodium Fluoride. The vials were sealed and inverted multiple times to mix the chemicals in the vials with the blood solution. All vials were placed in a refrigerator immediately after production until the sample sets were prepared.

SAMPLE SET ASSEMBLY: Each sample set contained two vials of each of the three Items and placed into a Department of Transportation regulated shipping container. The sample packs were then returned to the refrigerator until shipment.

VERIFICATION-

Laboratories that conducted predistribution analysis of the samples reported consistent results that were comparable to the preparation drug concentrations.

Item 1 Drug (Concentration)

Fentanyl (75 ng/mL)

Item 2 Drug (Concentration)

MDMA (345 ng/mL)

MDA (50 ng/mL)

11-nor-9-carboxy-delta-9-THC
(85 ng/mL)

Item 3 Drug (Concentration)

Oxycodone (150 ng/mL)

Noroxycodone (35 ng/mL)

Please note that the Preparation Value is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to wait for the Grand Mean statistics available in the Summary and Individual Reports before evaluating performance.

Summary Comments

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in blood. Each participant was supplied with two vials containing human blood spiked with differing drugs and/or metabolites for each of three case scenarios. Participants were asked to report the presence of any drugs/metabolites, quantitative data obtained (including uncertainty), methods used, and additional comments. (Refer to the Manufacturer's Information for preparation details.)

Of the 113 participants who reported screening results for Item 1, 57 (50.4%) reported the presence of opiates and/or fentanyl. Four of these participants also reported the presence of another drug class and/or analyte. Fifty-six (49.6%) participants reported "no drugs/metabolites detected". Of the 99 participants who reported confirmatory results for Item 1, 97 (98.0%) reported the presence of fentanyl and two participants reported "no drugs/metabolites detected."

Of the 113 participants who reported screening results for Item 2, 75 (66.4%) reported the presence of methamphetamine and/or MDMA. Sixty-seven (59.3%) reported the presence of amphetamine and/or MDA. Ninety-seven (85.8%) reported the presence of cannabinoids and/or THC-COOH. One participant reported "no drugs/metabolites detected" and four reported the presence of other drug classes and/or analytes. Of the 108 participants who reported confirmatory results for Item 2, 102 (94.4%) reported the presence of MDMA and 95 (88.0%) reported the presence of MDA. Eighty-six (80.0%) participants reported THC-COOH and four reported the presence of other analytes.

Of the 113 participants who reported screening results for Item 3, 97 (85.8%) reported the presence of opiates, oxycodone and/or noroxycodone. Sixteen (14.2%) reported "no drugs/metabolites detected" and four reported the presence of other drug classes and/or analytes. Of the 102 participants who reported confirmatory results for Item 3, 100 (98.0%) reported the presence of oxycodone and six participants also reported the presence of noroxycodone. One participant reported "no drugs/metabolites detected" and one reported the presence of MDMA.

If a participant indicated that the confirmatory quantitative result was a single determination and reported it in ng/mL, the conclusive quantitative result was included in the raw data table. The raw data was used to calculate the grand mean and standard deviation for each item and are supplied to assist the participants and accrediting bodies in determining the acceptability of results. For Item 1, one participant was determined to have "extreme" data (± 3 STD from grand mean) for fentanyl. For Item 2, one participant was determined to have "extreme" data for MDA and three participants were determined to have "extreme" data for THC-COOH. For Item 3, two participants were determined to have "extreme" data for oxycodone.

Screening Results - Item 1

TABLE 1A Item 1

Item Scenario:

The body of a 52 year old female was found in her home. Her lips and extremities were blue, foam was present around her mouth, and a syringe was found nearby. A blood sample was collected at the autopsy.

Item Contents and Preparation Concentration: Fentanyl (75 ng/mL)

| Webcode | Screening Results |
|---------|--|
| 2DPLGK | No drugs/metabolites detected |
| 2RDN2X | Fentanyl |
| 3RPK4H | fentanyl |
| 43M3WW | No drugs/metabolites detected |
| 46BFXM | Fentanyl |
| 4C8ATZ | Fentanyl |
| 4DHARF | Fentanyl |
| 4ZHB6H | No drugs/metabolites detected |
| 6DZMTX | fentanyl |
| 6FM2LE | Fentanyl |
| 79YZEZ | No drugs/metabolites detected |
| 7AD6BC | No drugs/metabolites detected |
| 7ATPXV | fentanyl |
| 7AVDZ8 | No drugs/metabolites detected |
| 7FH2YJ | No drugs/metabolites detected |
| 7FJ2UC | fentanyl |
| 7QGWWWE | No drugs/metabolites detected |
| 7ZUQCG | The immunoassay drug screen resulted in no drugs detected. The first GC/MS resulted in the detection of Fentanyl which needed to be confirmed using GC/MS. |
| 83RPZE | Fentanyl |
| 8NAYYQ | Fentanyl |
| 8T34RV | fentanyl |
| 8WMTC9 | Fentanyl |
| 9833FR | No drugs/metabolites detected |
| 9A48TC | No drugs/metabolites detected |
| 9ANN9F | No drugs/metabolites detected |
| 9F8CHB | Fentanyl and Zolpidem |
| 9JVLUX | No drugs/metabolites detected |
| 9KNGG7 | No drugs/metabolites detected |

TABLE 1A Item 1

| Webcode | Screening Results |
|----------------|--|
| 9LKREU | Fentanyl/ Acetyl Fentanyl |
| ABG2BX | Fentanyl |
| AHDRV9 | Possible Fentanyl, Possible Benzodiazepine |
| ALFUG4 | No drugs/metabolites detected |
| AN7YEG | Fentanyl (opioids) |
| AQCJ2G | FENTANYL |
| AWFMRF | Fentanyl |
| AYHL39 | Fentanyl |
| B2MB2B | Fentanyl |
| B2MB6G | Fentanyl |
| BBDW79 | Fentanyl |
| BF499W | Fentanyl |
| BGE937 | No drugs/metabolites detected |
| BHAUVW | Fentanyl |
| BKW9K8 | No drugs/metabolites detected |
| BM3VXB | No drugs/metabolites detected |
| BX2N9N | Fentanyl |
| C2JBF2 | No drugs/metabolites detected |
| CKVX4U | No drugs/metabolites detected |
| CMHCT6 | No drugs/metabolites detected |
| CQGQD9 | Fentanyl |
| DAVJLA | Fentanyl |
| DHM6M2 | No drugs/metabolites detected |
| DPKU9C | No drugs/metabolites detected |
| EJQEWA | No drugs/metabolites detected |
| EQXLY8 | No drugs/metabolites detected |
| EV6CW8 | No drugs/metabolites detected |
| F77W47 | No drugs/metabolites detected |
| FHXQA8 | fentanyl |
| FMTHH6 | Fentanyl |
| FWT6A2 | No drugs/metabolites detected |
| FZU93A | No drugs/metabolites detected |
| GGJE9H | Fentanyl |

TABLE 1A Item 1

| Webcode | Screening Results |
|----------------|-------------------------------|
| GX72E7 | Fentanyl |
| H9ZU49 | No drugs/metabolites detected |
| HEPCGY | No drugs/metabolites detected |
| HGDJ63 | Fentanyl |
| HZ9EF6 | No drugs/metabolites detected |
| J6E88E | No drugs/metabolites detected |
| J7TW97 | fentanyl |
| J7UKXW | No drugs/metabolites detected |
| JD9D32 | Fentanyl |
| JNRR2X | No drugs/metabolites detected |
| K6A8M6 | No drugs/metabolites detected |
| KL6674 | No drugs/metabolites detected |
| KXE9AX | Fentanyl |
| KXQ83L | Fentanyl |
| L67AMT | Fentanyl |
| LZEXPC | Fentanyl |
| M6MNQW | fentanyl |
| MVZKKH | No drugs/metabolites detected |
| MW9UE2 | No drugs/metabolites detected |
| N628BU | No drugs/metabolites detected |
| N7E2QU | No drugs/metabolites detected |
| N87Z6T | No drugs/metabolites detected |
| NJ37XQ | Fentanyl |
| PATW9D | Fentanyl |
| PB4ZHV | Fentanyl |
| R2PQAR | No drugs/metabolites detected |
| R4GR9N | No drugs/metabolites detected |
| RA2RQM | No drugs/metabolites detected |
| RNNZNN | No drugs/metabolites detected |
| RUNGZE | No drugs/metabolites detected |
| T23MAQ | Fentanyl |
| T7FKJY | Fentanyl |
| TC3B7U | No drugs/metabolites detected |

TABLE 1A Item 1

| Webcode | Screening Results |
|---------|-------------------------------|
| TD3DVX | Methadone & Fentanyl |
| TTCYGA | Fentanyl |
| U9HM6U | No drugs/metabolites detected |
| UV969K | No drugs/metabolites detected |
| UWVBV6 | No drugs/metabolites detected |
| UXY93R | No drugs/metabolites detected |
| UYA7X | No drugs/metabolites detected |
| V4LDER | No drugs/metabolites detected |
| VH3E8C | fentanyl |
| VKUATK | Fentanyl |
| VMDMCM | Fentanyl |
| VNVBXN | Fentanyl |
| W34NNK | No drugs/metabolites detected |
| WFW7GR | No drugs/metabolites detected |
| WYNJPP | Fentanyl |
| XBDFRN | Fentanyl |
| XMQWYK | Fentanyl |
| YC9F9Y | No drugs/metabolites detected |
| YXL4WP | Fentanyl |

| Response Summary for Item 1 | Participants: 113 |
|--|-------------------|
| Opiates and/or fentanyl: | 57 |
| Other: | 4 |
| No drugs/metabolites detected: | 56 |
| <p>Totals may add up to more than the total number of participants because participants can report multiple classes/drug names.</p> | |

Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?

TABLE 1B Item 1

Item Scenario:

The body of a 52 year old female was found in her home. Her lips and extremities were blue, foam was present around her mouth, and a syringe was found nearby. A blood sample was collected at the autopsy.

Item Contents and Preparation Concentration: Fentanyl (75 ng/mL)

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| 2DPLGK | Fentanyl | ✓ | | | |
| 2RDN2X | Fentanyl | ✓ | | | |
| 3RPK4H | fentanyl | | 58 | 17 | mcg/L |
| 43M3WW | Fentanyl | ✓ | | | |
| 46BFXM | Fentanyl | | 54 ug/l | 36% | ug/l |
| 4C8ATZ | Fentanyl | | 50 | 18 | ng/mL |
| 4DHARF | Fentanyl | | 54 | 17% | ng/mL |
| 4ZHB6H | Fentanyl | ✓ | | | |
| 6DZMTX | fentanyl | | 50 | 16 | ng/mL |
| 6FM2LE | Fentanyl | ✓ | | | |
| 7AD6BC | Fentanyl | ✓ | | | |
| 7ATPXV | fentanyl | | 63 | 20 | ng/mL |
| 7FH2YJ | Fentanyl | ✓ | | | |
| 7FJ2UC | fentanyl | | 55 | +/- 17 | µg/L |
| 7QGWWWE | Fentanyl | ✓ | | | |
| 7ZUQCG | Fentanyl | ✓ | | | |
| 83RPZE | Fentanyl | | 61 | 5 | ng/mL |
| 8NAYYQ | Fentanyl | ✓ | | | |
| 8T34RV | fentanyl | | 51 | 16 | ng/mL |
| 8WMTC9 | Fentanyl | ✓ | | | |
| 9833FR | Fentanyl | ✓ | | | |
| 9A48TC | Fentanyl | ✓ | | | |
| 9ANN9F | Fentanyl | ✓ | | | |
| 9F8CHB | Fentanyl | | 50 | +/- 15 | mcg/L |

TABLE 1B Item 1

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| 9KNGG7 | fentanyl | ✓ | | | |
| ABG2BX | Fentanyl | | 51 ug/L | ±15% | µg/L |
| AHDRV9 | Fentanyl | ✓ | | | |
| AN7YEG | Fentanyl | | 67.9 | ±13.7% | ng/mL |
| AQCJ2G | FENTANYL | | 100 | | ng/mL |
| AWFMRF | Fentanyl | ✓ | | | |
| AYHL39 | Fentanyl | ✓ | | | |
| B2MB2B | Fentanyl | ✓ | | | |
| B2MB6G | Fentanyl | ✓ | | | |
| BBDW79 | Fentanyl | ✓ | | | |
| BGE937 | Fentanyl | ✓ | | | |
| BHAUVW | Fentanyl | | 82 | | ng/mL |
| BKW9K8 | fentanyl | ✓ | | | |
| BM3VXB | Fentanyl | ✓ | | | |
| BX2N9N | Fentanyl | | 55 | 7.5 | ng/mL |
| CMHCT6 | Fentanyl | ✓ | | | |
| CQGQD9 | Fentanyl | | 50 | +/-15 | µg/L |
| DAVJLA | Fentanyl | ✓ | | | |
| DHM6M2 | Fentanyl | ✓ | | | |
| DPKU9C | Fentanyl | ✓ | | | |
| EJQEWA | Fentanyl | ✓ | Positive | | |
| EQXLY8 | Fentanyl | ✓ | | | |
| EV6CW8 | Fentanyl | ✓ | | | |
| F77W47 | Fentanyl | ✓ | | | |
| FHXQA8 | fentanyl | ✓ | | | |
| FMTHH6 | Fentanyl | | 55 | 16.5 | ng/mL |
| FWT6A2 | Fentanyl | ✓ | | | |
| FZU93A | fentanyl | ✓ | | | |
| GGJE9H | Fentanyl | ✓ | | | |
| GX72E7 | Fentanyl | ✓ | | | |

TABLE 1B Item 1

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| HEPCGY | fentanyl | ✓ | | | |
| HGDJ63 | Fentanyl | | 62.0 ng/mL | 2.9 | ng/mL |
| HZ9EF6 | Fentanyl | ✓ | | | |
| J7TW97 | fentanyl | ✓ | | | |
| J7UKXW | Fentanyl | ✓ | | | |
| JD9D32 | Fentanyl | | 70 ng/mL | 0.06 | ng/mL |
| JNRR2X | Fentanyl | ✓ | | | |
| K6A8M6 | Fentanyl | ✓ | Positive | | |
| KXE9AX | Fentanyl | ✓ | | | |
| KXQ83L | Fentanyl | | 63 | 5 | ng/mL |
| L67AMT | Fentanyl | | 62 | 12 | ng/mL |
| LZEXPC | Fentanyl | | 74 | 10 | ng/mL |
| M6MNQW | fentanyl | | 53 | 16 | µg/L |
| MW9UE2 | Fentanyl | ✓ | | | |
| N628BU | Fentanyl | ✓ | | | |
| N7E2QU | FENTANYL | | 58 | 17 | mcg/L |
| N87Z6T | Fentanyl | ✓ | | | |
| NJ37XQ | Fentanyl | | 70 | 7 | ng/mL |
| PATW9D | Fentanyl | ✓ | | | |
| PB4ZHV | Fentanyl | | 64 | 19 | ng/mL |
| R2PQAR | fentanyl | ✓ | | | |
| R4GR9N | Fentanyl | ✓ | | | |
| RA2RQM | Fentanyl | ✓ | | | |
| RNNZNN | Fentanyl | ✓ | | | |
| T7FKJY | Fentanyl | ✓ | | | |
| TC3B7U | Fentanyl | ✓ | | | |
| TD3DVX | Fentanyl | ✓ | | | |
| TTCYGA | Fentanyl | | 53.5 | 10.7 | ng/mL |
| U9HM6U | Fentanyl | ✓ | | | |
| UV969K | Fentanyl | ✓ | | | |

TABLE 1B Item 1

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|-------------------------------|------------------|------------------------|-------------|-------|
| UWVBV6 | Fentanyl | ✓ | | | |
| UXY93R | Fentanyl | ✓ | | | |
| UYA7X | No drugs/metabolites detected | | | | |
| V4LDER | Fentanyl | ✓ | | | |
| VH3E8C | fentanyl | | 50 | | ng/mL |
| VKUATK | Fentanyl | | 56 | 12 | ng/ml |
| VMDMCM | Fentanyl | ✓ | | | |
| VNVBXN | Fentanyl | ✓ | | | |
| W34NNK | Fentanyl | ✓ | | | |
| WFW7GR | Fentanyl | ✓ | | | |
| WYNJPP | Fentanyl | ✓ | | | |
| XBDFRN | Fentanyl | | 43 mcg/L | 13 | mcg/L |
| XMQWYK | Fentanyl | | 53 | +/-16 | mcg/L |
| YC9F9Y | No drugs/metabolites detected | | | | |
| YXL4WP | Fentanyl | ✓ | | | |

| Response Summary for Item 1 | | Participants: 99 |
|---|----|------------------|
| Fentanyl: | 97 | |
| No drugs/metabolites detected: | 2 | |
| Totals may add up to more than the total number of participants because participants can report multiple drugs/metabolites. | | |

Raw Data - Item 1

List of raw data determinations in ng/mL.

TABLE 1C Item 1
Item 1 Raw Data - Fentanyl
Preparation concentration: (75 ng/mL)

| Webcode | Raw Data (ng/mL) | | Participant Mean |
|---------|------------------|-------------|------------------|
| 3RPK4H | 57.96 | | 57.96 |
| 46BFXM | 54.00 | 46.00 | 50.00 |
| 4C8ATZ | 48.00 | 50.00 | 49.00 |
| 4DHARF | 54.45 | | 54.45 |
| 6DZMTX | 50.94 | | 50.94 |
| 7ATPXV | 63.35 | | 63.35 |
| 7FJ2UC | 55.09 | | 55.09 |
| 83RPZE | 60.00 | 62.00 | 61.00 |
| 8T34RV | 51.50 | | 51.50 |
| 9F8CHB | 49.73 | | 49.73 |
| ABG2BX | 51.56 | 51.34 | 51.45 |
| AN7YEG | 67.90 | 67.80 | 67.85 |
| AQCJ2G | 100.0 | | 100.0 X |
| BHAUVW | 82.16 | | 82.16 |
| BX2N9N | 55.00 | | 55.00 |
| CQGQD9 | 49.60 | | 49.60 |
| FMTTH6 | 57.89 | 53.44 | 55.66 |
| HGDJ63 | 62.00 | | 62.00 |
| JD9D32 | 70.00 | | 70.00 |
| KXQ83L | 62.79 | 63.35 | 63.07 |
| L67AMT | 62.00 | | 62.00 |
| LZEXPC | 74.00 | | 74.00 |
| M6MNPQW | 52.67 | | 52.67 |
| N7E2QU | 58.14 | | 58.14 |
| NJ37XQ | 71.65 | 68.85 | 70.25 |
| PB4ZHV | 63.91 | | 63.91 |
| TTCYGA | 53.30 | 52.40 54.80 | 53.50 |
| VH3E8C | 48.00 | 52.00 | 50.00 |

TABLE 1C Item 1
Item 1 Raw Data - Fentanyl
Preparation concentration: (75 ng/mL)

| Webcode | Raw Data (ng/mL) | Participant Mean |
|----------------|-------------------------|-------------------------|
| VKUATK | 56.00 | 56.00 |
| XBDFRN | 43.39 | 43.39 |
| XMQWYK | 53.44 | 53.44 |

| Statistical Analysis for Item 1 - Fentanyl | | |
|---|--------------|--|
| Grand Mean | 57.90 | Number of Participants Included 30 |
| Standard Deviation | 8.643 | Number of Participants Excluded 1 |
| | | Number of Participants without Raw Data or Data that was not reported in ng/mL 66 |

Reporting Procedures - Item 1

If quantitative analysis was performed, the reported concentrations are:

TABLE 1D Item 1

| Webcode | Quantitative Reporting Procedures |
|---------|---|
| 3RPK4H | A single determination. |
| 46BFXM | A single determination. |
| 4C8ATZ | The mean of duplicate/several determinations. |
| 4DHARF | A single determination. |
| 6DZMTX | A single determination. |
| 7ATPXV | A single determination. |
| 7FJ2UC | A single determination. |
| 8T34RV | A single determination. |
| 9F8CHB | A single determination. |
| 9KNGG7 | A single determination. |
| ABG2BX | The mean of duplicate/several determinations. |
| AN7YEG | The mean of duplicate/several determinations. |
| AQCJ2G | A single determination. |
| BHAUVW | A single determination. |
| BX2N9N | A single determination. |
| CQGQD9 | A single determination. |
| FMTTH6 | The mean of duplicate/several determinations. |
| HEPCGY | A single determination. |
| HGDJ63 | The mean of duplicate/several determinations. |
| JD9D32 | A single determination. |
| L67AMT | A single determination. |
| LZEXPC | A single determination. |
| M6MNPQW | A single determination. |
| N7E2QU | A single determination. |
| NJ37XQ | The mean of duplicate/several determinations. |
| PB4ZHV | A single determination. |
| TTCYGA | The mean of duplicate/several determinations. |
| VH3E8C | The mean of duplicate/several determinations. |
| VKUATK | A single determination. |

TABLE 1D Item 1

| Webcode | Quantitative Reporting Procedures |
|---------|-----------------------------------|
| XBDFRN | A single determination. |
| XMQWYK | A single determination. |
| YC9F9Y | A single determination. |

| Response Summary for Item 1 | Participants: 32 |
|---|------------------|
| A single determination: | 24 (75.0%) |
| The mean of duplicate/several determinations: | 8 (25.0%) |

Method of Analysis - Item 1

TABLE 1E Item 1

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|--------------|-----------|--------------|--------------|
| 2DPLGK | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 2RDN2X | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| 3RPK4H | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 43M3WW | LC/MS/MS | ✓ | ✓ | ✓ |
| | Immunoassay | ✓ | | |
| 46BFXM | GC/MS | | ✓ | |
| | LC/MS | | | ✓ |
| 4C8ATZ | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| | UPLC-QTOF MS | ✓ | | |
| 4DHARF | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| 4ZHB6H | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 6DZMTX | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 6FM2LE | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| 7AD6BC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| 7ATPXV | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 7AVDZ8 | Immunoassay | ✓ | | |
| 7FH2YJ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 7FJ2UC | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| 7QGWE | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 7ZUQCG | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 83RPZE | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| | LC-TOF | ✓ | | |

TABLE 1E Item 1

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|---|------------------|--------------|--------------|
| 8NAYYQ | Immunoassay GC/MS | ✓ | ✓ | |
| 8T34RV | GC/MS LC/MS/MS | ✓ | ✓ | ✓ |
| 8WMTC9 | GC/MS | ✓ | ✓ | |
| 9833FR | Immunoassay GC/MS | ✓ | ✓ | |
| 9A48TC | Immunoassay GC/MS | ✓ | ✓ | |
| 9ANN9F | Immunoassay GC/MS | ✓ | ✓ | |
| 9F8CHB | Immunoassay LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| 9JVLUX | Immunoassay | ✓ | | |
| 9KNGG7 | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |
| 9LKREU | Immunoassay | ✓ | | |
| ABG2BX | Immunoassay LC/MS/MS HPLC QTOF GC/FID | ✓ ✓ ✓ ✓ | ✓ | ✓ |
| AHDRV9 | Immunoassay GC/MS GC/NPD | ✓ ✓ ✓ | ✓ | |
| ALFUG4 | Immunoassay | ✓ | | |
| AN7YEG | LC/MS/MS | ✓ | ✓ | ✓ |
| AQCJ2G | GC/MS | ✓ | ✓ | |
| AWFMRF | Immunoassay GC/MS | ✓ | ✓ | |
| AYHL39 | Immunoassay GC/MS | ✓ ✓ | ✓ | |
| B2MB2B | Immunoassay GC/MS | ✓ ✓ | ✓ | |
| B2MB6G | Immunoassay GC/MS | ✓ | ✓ | |
| BBDW79 | Immunoassay GC/MS | ✓ | ✓ | |
| BF499W | Immunoassay | ✓ | | |
| BGE937 | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | |

TABLE 1E Item 1

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|----------------------------------|-----------|--------------|--------------|
| BHAUVW | Immunoassay GC/MS LC/MS/MS | ✓ | ✓ | ✓ |
| BKW9K8 | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | |
| BM3VXB | Immunoassay GC/MS | ✓ | ✓ | |
| BX2N9N | Immunoassay LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| C2JBF2 | Immunoassay | ✓ | | |
| CKVX4U | Immunoassay | ✓ | | |
| CMHCT6 | Immunoassay GC/MS GC\FID | ✓ | ✓ ✓ | |
| CQGQD9 | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | ✓ |
| DAVJLA | GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | |
| DHM6M2 | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | |
| DPKU9C | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | |
| EJQEWA | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | |
| EQXLY8 | Immunoassay LC/MS/MS | ✓ | ✓ | |
| EV6CW8 | Immunoassay GC/MS | ✓ | ✓ | |
| F77W47 | Immunoassay GC/MS | ✓ | ✓ | |
| FHXQA8 | Immunoassay GC/MS | ✓ ✓ | ✓ | |
| FMTHH6 | Immunoassay GC/MS LC/MS/MS | ✓ | ✓ ✓ | ✓ |
| FWT6A2 | GC/MS GC/FID | ✓ | ✓ | |
| FZU93A | Immunoassay GC/MS | ✓ | ✓ | |
| GGJE9H | Immunoassay GC/MS | ✓ | ✓ | |

TABLE 1E Item 1

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| GX72E7 | LC/MS/MS | ✓ | ✓ | |
| H9ZU49 | LC/MS/MS | ✓ | | |
| HEPCGY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| HGDJ63 | LC/MS | ✓ | | ✓ |
| | LC/MS/MS | | ✓ | |
| HZ9EF6 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| J6E88E | Immunoassay | ✓ | | |
| J7TW97 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| J7UKXW | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| | GC-HS | ✓ | | |
| JD9D32 | GC/MS | ✓ | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | |
| JNRR2X | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| K6A8M6 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| KL6674 | Immunoassay | ✓ | | |
| KXE9AX | LC/MS/MS | ✓ | ✓ | |
| KXQ83L | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| | QTOF | ✓ | | |
| L67AMT | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| LZEXPC | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| M6MNQW | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| MVZKKH | Immunoassay | ✓ | | |
| MW9UE2 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| N628BU | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC-FID | | ✓ | |
| N7E2QU | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | ✓ | ✓ | ✓ |

TABLE 1E Item 1

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| N87Z6T | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| NJ37XQ | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| PATW9D | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| PB4ZHV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| R2PQAR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| R4GR9N | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| RA2RQM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| RNNZNN | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| RUNGZE | Immunoassay | ✓ | | |
| T23MAQ | Immunoassay | ✓ | | |
| T7FKJY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TC3B7U | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TD3DVX | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TTCYGA | LC/MS/MS | ✓ | | ✓ |
| U9HM6U | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| UV969K | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| UVVBV6 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| UXY93R | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| UYA7X | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| V4LDER | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| VH3E8C | LC/MS/MS | ✓ | | ✓ |

TABLE 1E Item 1

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| VKUATK | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| VMDMCM | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| VNVBXN | LC/MS/MS | ✓ | ✓ | |
| W34NNK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC-FID | | ✓ | |
| WFW7GR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| WYNJPP | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| XBDFRN | LC/MS/MS | ✓ | ✓ | ✓ |
| XMQWYK | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| YC9F9Y | LC/MS/MS | ✓ | ✓ | ✓ |
| YXL4WP | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |

| Response Summary for Item 1 | | | Participants: 112 | | |
|-----------------------------|-----------|--------------|-------------------|--|--|
| | Screening | Confirmatory | Quantitation | | |
| Immunoassay: | 92 | 0 | 0 | | |
| GC/MS: | 29 | 68 | 2 | | |
| LC/MS: | 1 | 0 | 2 | | |
| LC/MS/MS: | 21 | 34 | 25 | | |
| Other: | 10 | 16 | 1 | | |

Additional Comments for Item 1

TABLE 1F Item 1

| Webcode | Item 1 - Comments |
|---------|---|
| 2DPLGK | Zolpidem indications, weak mass spectrum, assay negative - not reported |
| 2RDN2X | Fentanyl is usually reported quantitatively in our laboratory but the concentration for this proficiency sample was approximately three times the upper limit of quantitation for our analysis. Therefore, the value could not be reported out quantitatively. It could only be reported qualitatively. |
| 43M3WW | A second GC-MS extraction was conducted on 8/24/17 to confirm the fentanyl from the initial extraction on 7/27/17. |
| 4C8ATZ | Screening: Instrument: UPLC-QTOF MS (Waters) Salting-out assisted extraction. Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone. Fentanyl Quantitative Analysis: Instrument: UPLC-TQD (Waters). Internal Standard: D3-Codeine. LOD: 2 ng/mL |
| 4DHARF | Internal standard used was D5-Fentanyl. Limit of detection is 1.0 ng/mL (limit of quantitation is 1.67 ng/mL). |
| 6DZMTX | fentanyl internal standard = fentanyl-d5; LOQ = 0.5 ng/mL |
| 79YZEZ | Immunoassay analyte: cutoff - Amphetamine: 20 ng/mL, Methamphetamine: 20 ng/mL, Morphine: 20 ng/mL, Benzoylcegonine: 50 ng/mL, Oxazepam: 50 ng/mL, Carboxytetrahydrocannabinol: 20ng/mL. |
| 7AD6BC | IS = Mepivacaine. Even though death involved, Fentanyl is not quantitated in lab. |
| 7ATPXV | fentanyl internal standard = fentanyl-d5; LOQ = 0.5 ng/mL |
| 7AVDZ8 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone, phencyclidine, and zolpidem. Laboratory does not routinely analyze postmortem samples (outside scope of testing). |
| 7FJ2UC | mepivacaine |
| 7QGWWE | Internal standard: Mepivacaine |
| 7ZUQCG | Internal standards used: Mepivacaine, Nalorphine. Zolpidem indicated: not reported, immunoassay not indicative |
| 83RPZE | Internal standard: Fentanyl-D5. LOD: 0.63 ng/mL. LOQ: 1.25 ng/mL. Diluted 5-fold for quantitation |
| 8T34RV | fentanyl internal standard = fentanyl-d5; LOQ = 0.5 ng/mL |
| 8WMTC9 | Mepivacaine used as an internal standard. Fentanyl limit of detection: 50 ng/mL. |
| 9A48TC | Zolpidem indicated, may be an artifact from production, not reported. |
| 9F8CHB | Internal standard used was mepivacaine. The limit of detection is 0.5 mcg/L for fentanyl. |
| 9KNGG7 | Fentanyl is only called positive and not quantitated via GC/FID |
| ABG2BX | D5 - Fentanyl used as internal standard for confirmation/quantitation by LCMSMS. LOQ is 1 ng on column. |
| AHDRV9 | Butyl Acetate Screen - Promazine (IStd). Opiate Confirmation - Nalorphine (IStd) |
| ALFUG4 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone. Our laboratory does not routinely test post-mortem blood. |
| BHAUVW | ULOQ for method is 30 ng/mL. Dilution was required. |

TABLE 1F Item 1

| Webcode | Item 1 - Comments |
|---------|--|
| BKW9K8 | Internal Standard= Mepivacaine. It is our policy to call fentanyl positive only. We do not quantitate this drug. |
| BM3VXB | Internal standard used: Mepivacaine |
| BX2N9N | Internal standard is Fentanyl-D5. Detection limit is 1 ng/mL for Fentanyl |
| C2JBF2 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone, phencyclidine, and zolpidem. Laboratory does not routinely analyze postmortem samples (outside scope of testing). |
| CKVX4U | The sample was screened for the following type/class of drugs: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, PCP |
| CMHCT6 | The lab does not quantitate Fentanyl. |
| CQGQD9 | Internal standard-mepivacaine. Had to sample reduced volume to get quantitation on calibration curve. 50 μ L sampled for a 200 μ L extraction, result multiplied by 4. |
| DHM6M2 | Fentanyl is not quantitated using our basic extraction. It is only identified as positive. |
| EJQEWA | For fentanyl, the GC-FID was qualitative only. |
| EQXLY8 | We used Fentanyl -D5 as internal standard. |
| EV6CW8 | Internal Standard: Mepivacaine |
| F77W47 | Internal Standards used: Mepivacaine. Fentanyl Limit of Detection: 50 ng/mL |
| FHXQA8 | Caffeine and ibuprofen were also confirmed in the blood sample. The drugs were not reported independently in sections 1-1 [Table 1A - Screening Results-Item 1] and 1-2 [Table 1B - Confirmatory Results-Item 1] because they were confirmed in more than one of the PT samples. |
| HGDJ63 | Internal Standard = Estazolam (1000 ng/mL) |
| HZ9EF6 | Internal standard for confirmatory testing: Mepivacaine |
| JD9D32 | LOD = 10 ng/mL. Internal Standard (GC/MS) = Nalorphine. Internal Standard (LC/MS/MS) = Flurazepam |
| JNRR2X | Internal standard used is mepivacaine. We have external testing done fentanyl, we call it positive. |
| KXE9AX | Internal Standard = Estazolam |
| KXQ83L | Initial quantitation of fentanyl was above the standard curve (high standard 40 ng/mL); the sample was analyzed again but with a dilution factor of 2. |
| L67AMT | Internal Standard: d5-Fentanyl. LOD: 0.4 ng/mL. LOQ: 0.4 ng/mL |
| LZEXPC | Internal standard is Fentanyl-D5. Detection limit is 1 ng/mL for Fentanyl |
| M6MNQW | IS: mepivacaine. LOD: 0.5 μ g/L. |
| MVZKKH | Our immunoassay screening (ELISA) panel includes Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates and Phencyclidine. |
| N7E2QU | mepivacaine used as internal standard. |
| N87Z6T | The lab does not quantitate Fentanyl. |
| NJ37XQ | LOQ 1 ng/mL. Internal standard Fentanyl-D5 |

TABLE 1F Item 1

| Webcode | Item 1 - Comments |
|---------|--|
| PATW9D | Used Internal standards: For the screening: Phenobarbital D-5; For the Confirmatory: Codeine D-3 |
| PB4ZHV | Internal standard: mepivacaine |
| R4GR9N | I.S. = Mepivacaine |
| RNNZNN | Internal Standard - Mepivacaine. Fentanyl LOD - 50 ng/ml. Oxycodone and Zolpidem were indicated but not reported. |
| RUNGZE | Screen for following w/ cut-off values: Amp 20ng/ml, Oxa 50ng/ml, BE 50ng/ml, Meth 20ng/ml, Morphine 20ng/ml, C-THC 20ng/ml. |
| T23MAQ | [From Table 1B - Confirmatory Results-Item 1: "No validated method available at this time."] |
| TC3B7U | Internal Standard: Mepivacaine. Compounds indicated but not reported: Codeine and Zolpidem |
| TTCYGA | Fentanyl-D5 as ISTD. LOQ - 2 ng/mL |
| U9HM6U | Internal standards - SKF-525A @ 500 ng/mL |
| UV969K | Internal Standard: Mepivacaine. Fentanyl LOD 50ng/mL |
| VH3E8C | nordiazepam-d5 as internal standard, LOD 0.2ng/mL |
| VKUATK | fentanyl - d5 |
| VMDMCM | Butyl Acetate screen utilized Promazine internal standard. |
| WFW7GR | The Lab does not quantitate Fentanyl. |
| XBDFRN | internal standards: mepivacaine |
| XMQWYK | Internal standard used: mepivacaine. Full volume for CQ LCMSMS quantitation was higher than the highest calibrator. Analysis was calculated from 1:10 dilution single determination. |

Screening Results - Item 2

TABLE 2A Item 2

Item Scenario:

A 26 year old female was arrested at a party. The arresting officer noted that she exhibited sweating, chills, dilated pupils, and confusion. A blood sample was collected 80 minutes after the arrest.

Item Contents and Preparation Concentration: MDMA (345 ng/mL)
MDA (50 ng/mL)
11-Nor-9-carboxy-delta-9-THC (85 ng/mL)

| Webcode | Screening Results |
|---------|--|
| 2DPLGK | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| 2RDN2X | 3,4-MDMA, 3,4-MDA, Delta 9 Carboxy-THC |
| 3RPK4H | cannabinoids, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA) |
| 43M3WW | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| 46BFXM | sympathomimetic amines |
| 4C8ATZ | 3,4-Methylenedioxyamphetamine (3,4-MDA), 3,4-Methylenedioxymethylamphetamine (3,4-MDMA), Delta-9-THC Acid |
| 4DHARF | 11-nor-Delta-9-Carboxy-THC, Methamphetamine & MDMA |
| 4ZHB6H | Methamphetamine, Cannabinoids |
| 6DZMTX | amphetamines; MDA, MDMA, cannabinoids; 11-nor-9-carboxy-delta9-THC |
| 6FM2LE | Sympathomimetic amines |
| 79YZEZ | Amphetamine, Methamphetamine, Tetrahydrocannabinol |
| 7AD6BC | Cannabinoids |
| 7ATPXV | amphetamines; MDA, MDMA, cannabinoids; 11-nor-9-carboxy-delta9-THC |
| 7AVDZ8 | Cannabinoids, amphetamine |
| 7FH2YJ | Cannabinoids |
| 7FJ2UC | THC class, MDA (3,4-methylenedioxyamphetamine), MDMA (3,4-methylenedioxymethamphetamine) |
| 7QGWWWE | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| 7ZUQCG | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| 83RPZE | Methylenedioxymethamphetamine (MDMA), Methylenedioxyamphetamine (MDA) |
| 8NAYYQ | Cannabinoids, Methamphetamine/MDMA |
| 8T34RV | amphetamines; MDA, MDMA, cannabinoids; 11-nor-9-carboxy-delta9-THC |
| 8WMTC9 | Amphetamine/MDA; Cannabinoids; Methamphetamine/MDMA. |
| 9833FR | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| 9A48TC | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |

TABLE 2A Item 2

| Webcode | Screening Results |
|---------|--|
| 9ANN9F | THC, Methamphetamine |
| 9F8CHB | delta-9 THC and metabolite(s), MDA, and MDMA |
| 9JVLUX | Amphetamines, Cannabinoids |
| 9KNGG7 | cannabinoids |
| 9LKREU | Cannabinoids, Amphetamines, Methamphetamine/MDMA |
| ABG2BX | Illicit stimulants: (MDA: 3,4-dimethylenedioxyamphetamines), (MDA: methylenedioxyamphetamine) |
| AHDRV9 | Possible SMA , Possible Benzodiazepine |
| ALFUG4 | amphetamine, cannabinoids |
| AN7YEG | MDA (illicit hallucinogens/stimulants), MDMA (illicit hallucinogens/stimulants), THC-COOH (cannabinoids) |
| AQCJ2G | AMPHETAMINE/EXTASIS, CANNABIS |
| AWFMRF | MDMA |
| AYHL39 | Methamphetamine, Cannabinoids |
| B2MB2B | Amphetamine/MDA, Methamphetamine/MDMA, Cannabinoids |
| B2MB6G | MDMA |
| BBDW79 | Methamphetamine (MDMA), Cannabinoids |
| BF499W | Amphetamine, Cannabinoids, MDMA, Methamphetamine |
| BGE937 | Marijuana metabolites |
| BHAUVW | Methamphetamine, Amphetamine, Cannabinoid |
| BKW9K8 | Cannabinoids |
| BM3VXB | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| BX2N9N | 11-nor-9-Carboxy-delta9-THC, 3,4-methylenedioxyamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) |
| C2JBF2 | Cannabinoids and amphetamine. |
| CKVX4U | Cannabinoids, Amphetamines |
| CMHCT6 | THC |
| CQGQD9 | Cannabinoids, MDA, MDMA |
| DAVJLA | MDMA, MDA, THC-COOH |
| DHM6M2 | THC and metabolites |
| DPKU9C | THC and metabolites |
| EJQEWA | Cannabinoids presumptively positive. |

TABLE 2A Item 2

| Webcode | Screening Results |
|---------|---|
| EQXLY8 | We detected cannabinoids |
| EV6CW8 | Amphetamine/MDA, Methamphetamine/MDMA, Cannabinoids |
| F77W47 | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| FHXQA8 | amphetamine, cannabinoids, methamphetamine |
| FMTHH6 | Delta 9 Carboxy THC, MDMA, MDA |
| FWT6A2 | THC (ELISA) |
| FZU93A | THC |
| GGJE9H | Amphetamines, THC |
| GX72E7 | MDA, MDMA, Carboxy-THC |
| H9ZU49 | MDMA, MDA, THC-COOH |
| HEPCGY | THC ELISA screen |
| HGDJ63 | MDMA |
| HZ9EF6 | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| J6E88E | Methamphetamine, Amphetamine, MDMA (3,4 Methyleneoxy-Methamphetamine), THC (Tetrahydrocannabinol) |
| J7TW97 | Cannabinoids, amphetamine, methamphetamine |
| J7UKXW | No drugs/metabolites detected |
| JD9D32 | 3,4-Methylenedioxymethamphetamine (MDMA) |
| JNRR2X | Cannabinoids |
| K6A8M6 | THC |
| KL674 | Cannabinoids, methamphetamine |
| KXE9AX | MDMA |
| KXQ83L | Methylenedioxymethamphetamine, methylenedioxyamphetamine, carboxytetrahydrocannabinol |
| L67AMT | THC-Metabolite, Amphetamine, and Methamphetamine |
| LZEXPC | 11-nor-9-Carboxy-delta 9-THC, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA) |
| M6MNQW | cannabinoids, 3,4-methylenedioxymethamphetamine, 3,4-methyldioxyamphetamine |
| MVZKXH | Positive for Amphetamines and Cannabinoids. |
| MW9UE2 | The specimen screened positive for THC using EMIT technology screening. |
| N628BU | Cannabinoids |
| N7E2QU | class - Cannabinoids |

TABLE 2A Item 2

| Webcode | Screening Results |
|---------|---|
| N87Z6T | THC |
| NJ37XQ | Amphetamine, Methamphetamine, Cannabinoids |
| PATW9D | MDMA, MDA, 11-nor-9-carboxy- delta-9-THC |
| PB4ZHV | 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) |
| R2PQAR | Drug(s) detected [No class and/or drug names reported] |
| R4GR9N | Cannabinoids |
| RA2RQM | Cannabinoids |
| RNNZNN | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| RUNGZE | Amp, Meth, THC |
| T23MAQ | Methamphetamines, amphetamines, marijuana metabolite |
| T7FKJY | MDMA and Cannabinoids |
| TC3B7U | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| TD3DVX | Cannabinoids & MDMA |
| TTCYGA | Methylenedioxymethamphetamine (MDMA), Methylenedioxyamphetamine (MDA) |
| U9HM6U | Amphetamine, Methamphetamine, Cannabinoids |
| UV969K | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| UVVBV6 | Amphetamine/MDA, Cannabinoids, Methamphetamine/MDMA |
| UXY93R | amphetamine, methamphetamine, cannabinoids |
| UYA7X | Amphetamines, Methamphetamine, Marijuana Metabolite |
| V4LDER | Cannabinoids |
| VH3E8C | MDMA, MDA |
| VKUATK | THC, MDMA |
| VMDMCM | Sympathomimetic Amines (SMA) |
| VNVBXN | 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine |
| W34NNK | Cannabinoids |
| WFW7GR | THC |
| WYNJPP | Methamphetamine/Amphetamine/Cannabinoid ELISA Screens, MDMA, MDA |
| XBDFRN | Cannabinoids, MDA, MDMA |
| XMQWYK | THC, MDMA, MDA |
| YC9F9Y | 3,4-MDMA, THCCOOH |

TABLE 2A Item 2

| Webcode | Screening Results |
|----------------|--|
| YXL4WP | Amphetamine, Cannabinoids (THC), Methamphetamine |

| Response Summary for Item 2 | Participants: 113 |
|---|--------------------------|
| Methamphetamine and/or MDMA: | 75 |
| Amphetamine and/or MDA: | 67 |
| Cannabinoids and/or THC-COOH: | 97 |
| Other: | 4 |
| No drugs/metabolites detected: | 1 |
| Totals may add up to more than the total number of participants because participants can report multiple drugs/analytes. | |

Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?

TABLE 2B Item 2

Item Scenario:

A 26 year old female was arrested at a party. The arresting officer noted that she exhibited sweating, chills, dilated pupils, and confusion. A blood sample was collected 80 minutes after the arrest.

Item Contents and Preparation Concentration: MDMA (345 ng/mL)
MDA (50 ng/mL)
11-Nor-9-carboxy-delta-9-THC (85 ng/mL)

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| 2DPLGK | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 89 | 27% | ng/mL |
| 2RDN2X | 3,4 - MDMA | | 304.4 | 48.7 | ng/ml |
| | 3,4 - MDA | ✓ | | | |
| | Delta-9 Carboxy THC | ✓ | | | |
| 3RPK4H | 3,4-methylenedioxymethamphetamine | | 400 | 90 | mcg/L |
| | 3,4-methylenedioxyamphetamine | | 61 | 14 | mcg/L |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 69 | 12 | ng/mL |
| 43M3WW | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THCA | | 78 | 27 | ng/ml |
| 46BFXM | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| 4C8ATZ | 3,4-Methylenedioxymethylamphetamine | | 380 | 85 | ng/mL |
| | 3,4-Methylenedioxyamphetamine | | 50 | 30 | ng/mL |
| | Delta-9-THC Acid | | 96 | 18 | ng/mL |
| 4DHARF | Methylenedioxymethamphetamine (MDMA) | | 310 | 18% | ng/mL |
| | Methylenedioxyamphetamine (MDA) | | 40 | 18% | ng/mL |
| | 11-nor-Delta-9-Carboxy-THC, Free | ✓ | | | |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| 4ZHB6H | 3,4-Methylenedioxyamphetamine | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine | ✓ | | | |
| | Delta-9 Carboxy THC | ✓ | | | |
| 6DZMTX | MDMA | | 310 | 42 | ng/mL |
| | MDA | | 43 | 6.1 | ng/mL |
| | 11-nor-9-carboxy-delta9-THC | | 72 | 11 | ng/mL |
| 6FM2LE | MDMA | | | | |
| | MDA | ✓ | | | |
| 79YZEZ | MDMA | | 0.308 | ±0.046 | µg/mL |
| | MDA | | 0.047 | ±0.007 | µg/mL |
| | Carboxytetrahydrocannabinol | | 68 | ±11 | ng/mL |
| 7AD6BC | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 84 | +/- 11 | ng/mL |
| 7ATPXV | MDMA | | 340 | 45 | ng/mL |
| | MDA | | 47 | 6.6 | ng/mL |
| | 11-nor-9-carboxy-delta9-THC | | 88 | 13 | ng/mL |
| 7AVDZ8 | 11-nor-9-carboxy-delta-9-tetrahydrocannabinol | | 81 | ± 12 | ng/mL |
| 7FH2YJ | MDMA | | 0.35 | +/-0.02 | ug/ml |
| | MDA | | 0.06 | +/-0.004 | ug/ml |
| | 11-nor-9-carboxy-delta9-THC | | 85 | +/-11 | ng/ml |
| 7FJ2UC | MDMA (3,4-methylenedioxyamphetamine) | | 0.43 | +/- 0.10 | mg/L |
| | MDA (3,4-methylenedioxyamphetamine) | | 68 | +/- 16 | µg/L |
| | THCCOOH (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid) | | 74 | +/- 13 | ng/mL |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| 7QGWWE | 3,4-methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 83 | 27 | ng/mL |
| 7ZUQCG | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 78 | +/- 27% | ng/mL |
| 83RPZE | MDMA | | 0.28 | 0.04 | mg/L |
| | MDA | | 0.046 | 0.009 | mg/L |
| 8NAYYQ | MDMA | | 310 | | ng/mL |
| | MDA | ✓ | | | |
| | THC-COOH | ✓ | | | |
| 8T34RV | MDMA | | 340 | 45 | ng/mL |
| | MDA | | 48 | 6.8 | ng/mL |
| | 11-nor-9-carboxy-delta9-THC | | 79 | 11 | ng/mL |
| 8WMTC9 | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 86 | 27% | ng/mL |
| 9833FR | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 70 | 27% | ng/ml |
| 9A48TC | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 89 | +/- 27% | ng/mL |
| 9ANN9F | MDMA | ✓ | | | |
| | MDA | ✓ | | | |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|---|------------------|------------------------|-------------|-------|
| 9F8CHB | 3,4-methylenedioxyamphetamine | | 0.41 | +/- 0.09 | mg/L |
| | 3,4-methylenedioxyamphetamine | | 65 | +/- 15 | mcg/L |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 83 | +/- 14 | ng/mL |
| 9KNGG7 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 93 | +/- 12 | ng/mL |
| ABG2BX | MDMA (3,4-methylenedioxyamphetamine) | | 0.32 | ±10% | mg/L |
| | MDA (methylenedioxyamphetamine) | | 0.04 | ±10% | mg/L |
| AHDRV9 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| ALFUG4 | 11-nor-9-carboxy-delta-9-cannabinnol | | 77 | 11 | ng/mL |
| AN7YEG | MDMA | | 398.5 | ±14.1% | ng/mL |
| | MDA | | 52.5 | ±13.6% | ng/mL |
| | THC-COOH | | 84.8 | ±14.4% | ng/mL |
| AQCJ2G | MDMA | | 404 | | ng/mL |
| | MDA | | 50 | | ng/mL |
| | 11-nor-d9-THC-COOH | | 32 | | ng/mL |
| AWFMRF | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| AYHL39 | 3,4-Methylenedioxyamphetamine | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine | ✓ | | | |
| | Delta-9 Carboxy THC | ✓ | | | |
| B2MB2B | 3,4-Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 86 | 27% | ng/ml |
| B2MB6G | MDMA | ✓ | | | |
| | MDA | ✓ | | | |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| BBDW79 | MDMA | ✓ | | | |
| BF499W | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | ✓ | | | |
| BGE937 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | 11-nor-9-carboxy-delta-9-THC | | 91 | +/- 12 | ng/mL |
| BHAUVW | 3,4-Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 9-carboxy-11-nor-delta-9-THC | | 69 | | ng/mL |
| BKW9K8 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 91 | (80-104) | ng/mL |
| BM3VXB | 3,4-Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 86 | 27% | ng/mL |
| BX2N9N | MDMA | | 293 | 54 | ng/mL |
| | MDA | | 68 | 6.7 | ng/mL |
| | 11-nor-9-Carboxy-delta9-THC | | 102 | 14 | ng/mL |
| C2JBF2 | 11-nor-9-carboxy-delta-9-THC | | 80 | ±12 | ng/ml |
| CMHCT6 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | 11-nor-9-carboxy-delta-9-THC | | 90 | +/- 12 | ng/mL |
| CQGQD9 | 3,4-methylenedioxyamphetamine | | 0.41 | 0.09 | mg/L |
| | 3,4-methylenedioxyamphetamine | | 55 | +/-13 | µg/L |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 67 | +/-11 | ng/mL |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| DAVJLA | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | ✓ | | | |
| DHM6M2 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH (Carboxy THC) | | 95 | +/- 13 | ng/mL |
| DPKU9C | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | 11-nor-9-carboxy-delta-9-THC | | 86 | +/-11 | ng/ml |
| EJQEWA | MDMA | ✓ | Positive | | |
| | MDA | ✓ | Positive | | |
| | 11-nor-9-carboxy-delta-9-THC | | 87 | +/- 11 | ng/mL |
| EQXLY8 | MDMA | ✓ | | | |
| | delta-9-tetrahydrocannabinol-9-carboxylic acid | ✓ | | | |
| EV6CW8 | 3,4-Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 88 | +/-27% | ng/ml |
| F77W47 | 3,4-Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 83 | 27% | ng/mL |
| FHXA8 | methylenedioxyamphetamine | ✓ | | | |
| | methylenedioxyamphetamine | ✓ | | | |
| | carboxy-THC | ✓ | | | |
| FMTTH6 | MDMA | | 289 | 86.7 | ng/mL |
| | MDA | | 55 | 16.5 | ng/mL |
| | Delta 9 carboxy THC | | 72 | 21.6 | ng/mL |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| FWT6A2 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 83.0 | +/-11.0 | ng/ml |
| FZU93A | MDMA | | 0.37 | 0.02 | ug/ml |
| | MDA | | 0.07 | 0.005 | ug/ml |
| | 11-nor-9-carboxy-delta-9-THC | | 86 | 11 | ng/ml |
| GGJE9H | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | 11-nor-9-carboxy-THC | ✓ | | | |
| GX72E7 | 3,4-methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-methylenedioxyamphetamine (MDA) | ✓ | | | |
| | Carboxy-THC | ✓ | | | |
| HEPCGY | MDMA | ✓ | positive | | |
| | MDA | ✓ | positive | | |
| | 9-carboxy-11-nor-delta-9-THC | | 92 | 81-105 | ng/mL |
| HGDJ63 | MDMA | | 335.7 ng/mL | 7.0 | ng/mL |
| HZ9EF6 | 3,4-Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 81 | 27% | ng/ml |
| J7TW97 | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 72 | | ng/mL |
| J7UKXW | MDMA | ✓ | | | |
| JD9D32 | MDMA | ✓ | >300 ng/mL | 0.06 | ng/mL |
| JNRR2X | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | thc-cooh | | 95 | 83-108 | ng/ml |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|---|------------------|------------------------|-------------|-------|
| K6A8M6 | MDMA | | 0.34 | +/-0.02 | ug/ml |
| | MDA | | 0.07 | +/-0.005 | ug/ml |
| | 11-nor--9-carboxy-delta-9-THC | | 81 | +/-10 | ng/ml |
| KLG674 | Cannabinoids | ✓ | | | |
| | Methamphetamine | ✓ | | | |
| KXE9AX | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| KXQ83L | Methylenedioxyamphetamine | | 0.33 | 0.04 | mg/L |
| | Methylenedioxyamphetamine | | 0.055 | 0.007 | mg/L |
| | Carboxytetrahydrocannabinol | ✓ | | | |
| L67AMT | 3,4-Methylenedioxyamphetamine (MDMA) | | 302 | 60 | ng/mL |
| | 3,4-Methylenedioxyamphetamine (MDA) | | 44 | 9 | ng/mL |
| | 11-nor-9-carboxy-delta-9-THC | | 84 | 17 | ng/mL |
| LZEXPC | 3,4-methylenedioxyamphetamine (MDMA) | | 334 | 62 | ng/mL |
| | 3,4-methylenedioxyamphetamine (MDA) | | 63 | 6.2 | ng/mL |
| | 11-nor-9-Carboxy-delta 9-THC | | 87 | 12 | ng/ml |
| M6MNQW | 3,4-methylenedioxyamphetamine | | 0.41 | 0.09 | mg/L |
| | 3,4-methyldioxyamphetamine | | 64 | 15 | μg/L |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 71 | 12 | ng/mL |
| MVZKKH | THCA | | 92 | 14.7 | ng/mL |
| MW9UE2 | Oxycodone | ✓ | | | |
| N628BU | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 86 | 75-97 | ng/ml |
| N7E2QU | MDMA | | 0.41 | 0.09 | mg/L |
| | MDA | | 67 | 15 | mcg/L |
| | THC-COOH | | 84 | 14 | ng/mL |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|--------|
| N87Z6T | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | [No analyte name reported] | | 51 | +/- 5 | ng/mL |
| NJ37XQ | MDMA | | 0.39 | 0.05 | mg/L |
| | MDA | | 0.050 | 0.006 | mg/L |
| | Cannabinoids | ✓ | | | |
| PATW9D | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | 11-nor-9-carboxy- delta-9-THC | ✓ | | | |
| PB4ZHV | MDMA | | 400 | 90 | ng/mL |
| | MDA | | 62 | 14 | ng/mL |
| | THC-COOH | | 80 | 14 | ng/mL |
| R2PQAR | methylenedioxymethamphetamine | ✓ | | | |
| | methylenedioxyamphetamine | ✓ | | | |
| | carboxy-THC | ✓ | | | |
| R4GR9N | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 96 ng/mL | +/- 13 | ng/mL |
| RA2RQM | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 101 | +/- 13 | ng/mL |
| RNNZNN | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) | | 84 | +/- 27% | ng/ml |
| RUNGZE | MDMA | | 0.334 | ±0.050 | mcg/ml |
| | MDA | | 0.049mcg/ml | ±0.008 | mcg/ml |
| | C-THC | | 75 | ±12 | ng/ml |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| T23MAQ | 3,4-Methylenedioxymethamphetamine MDMA | | 284 | | ng/mL |
| | 3,4-Methylenedioxyamphetamine MDA | | 50 | | ng/mL |
| | 11-nor-9-carboxy-delta-9-THC | | 78 | | ng/mL |
| T7FKJY | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THCA | | 62.2 | 21.6 | ng/mL |
| TC3B7U | 3,4-Methylenedioxymethamphetamine (MDMA) | ✓ | | | |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9- carboxylic acid (THCA) | | 81 | +/- 27% | ng/ml |
| TD3DVX | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| TTCYGA | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| U9HM6U | Methylenedioxymethamphetamine | ✓ | | | |
| | carboxy-THC | ✓ | | | |
| UV969K | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THCA | | 87 | 27% | ng/mL |
| UVBV6 | 3,4-methylenedioxymethamphetamine | ✓ | | | |
| | 3,4-methylenedioxyamphetamine | ✓ | | | |
| | 11-nor-delta-9-tetrahydrocannabinol-9- carboxylic acid (THCA) | | 86 | 21% | ng/ml |
| UXY93R | methylenedioxymethamphetamine | ✓ | | | |
| | methylenedioxyamphetamine | ✓ | | | |
| | carboxy-THC | ✓ | | | |
| UYA7X | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | Carboxy-THC (THCCOOH) | | 75 | 15 | ng/mL |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|---|------------------|------------------------|-------------|-------|
| V4LDER | MDMA | | 0.38 | +/- 0.03 | ug/ml |
| | MDA | | 0.07 | +/- 0.005 | ug/ml |
| | 11-nor-9-carboxy-delta-9-THC | | 88 | +/- 11.00 | ng/ml |
| VH3E8C | MDMA | | 330 | | ng/mL |
| | MDA | | 94 | | ng/L |
| VKUATK | MDMA | | 307 | 62 | ng/ml |
| | MDA | | 46 | 10 | ng/ml |
| | 11-carboxy-THC | | 80 | 20 | ng/ml |
| VMDMCM | Methylenedioxyamphetamine (MDMA) | ✓ | | | |
| | Methylenedioxyamphetamine (MDA) | ✓ | | | |
| VNVBXN | 3,4-methylenedioxyamphetamine | ✓ | | | |
| | 3,4-methylenedioxyamphetamine | ✓ | | | |
| W34NNK | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | THC-COOH | | 90 | +/-12 | ng/ml |
| WFW7GR | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | 11-nor-9-carboxy-9-THC | | 57 | +/- 7 | ng/mL |
| WYNJPP | MDMA | ✓ | | | |
| | MDA | ✓ | | | |
| | Delta-9-Carboxy THC | | 89 | 36% | ng/mL |
| XBDFRN | 3,4-methylenedioxyamphetamine | | 0.43 mg/L | 0.10 | mg//L |
| | 3,4-methylenedioxyamphetamine | | 64 mcg/L | 15 | mcg/L |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 68 ng/mL | 12 | ng/mL |
| XMQWYK | 3,4-methylenedioxyamphetamine | | 0.41 | +/-0.09 | mg/L |
| | 3,4-methylenedioxyamphetamine | | 64 | +/-15 | mcg/L |
| | 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid | | 76 | +/-13 | ng/mL |

TABLE 2B Item 2

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|--|------------------|------------------------|-------------|-------|
| YC9F9Y | 3,4-MDMA | | 332.90 | 166.45 | ng/ml |
| | THCCOOH | | 241.00 | 120.50 | ng/ml |
| YXL4WP | 3,4-Methylenedioxymethamphetamine (MDMA) | | 366.0 | | ng/mL |
| | 3,4-Methylenedioxyamphetamine (MDA) | ✓ | | | |
| | Carboxy-THC | | 44.0 | | ng/mL |

| Response Summary for Item 2 | Participants: 108 |
|--|-------------------|
| MDMA: 102 | |
| MDA: 95 | |
| 11-nor-9-carboxy-delta-9-THC: 86 | |
| Other: 4 | |
| <p>Totals may add up to more than the total number of participants because participants can report multiple drugs/metabolites.</p> | |

Raw Data - Item 2

List of raw data determinations in ng/mL.

TABLE 2C Item 2
Item 2 Raw Data - MDMA
Preparation concentration: (345 ng/mL)

| Webcode | Raw Data (ng/mL) | | Participant Mean | | |
|---------|------------------|-------|------------------|-------|-------|
| 2RDN2X | 304.0 | | 304.0 | | |
| 3RPK4H | 402.7 | | 402.7 | | |
| 4C8ATZ | 370.0 | 384.0 | 377.0 | | |
| 4DHARF | 310.0 | | 310.0 | | |
| 6DZMTX | 315.8 | | 315.8 | | |
| 79YZEZ | 308.0 | | 308.0 | | |
| 7ATPXV | 341.0 | | 341.0 | | |
| 7FH2YJ | 350.0 | | 350.0 | | |
| 7FJ2UC | 427.8 | | 427.8 | | |
| 83RPZE | 275.0 | 287.0 | 281.0 | | |
| 8NAYYQ | 311.2 | | 311.2 | | |
| 8T34RV | 343.5 | | 343.5 | | |
| 9F8CHB | 414.0 | | 414.0 | | |
| ABG2BX | 315.0 | 318.0 | 316.5 | | |
| AN7YEG | 386.0 | 410.9 | 398.5 | | |
| AQCJ2G | 404.0 | | 404.0 | | |
| BX2N9N | 293.0 | | 293.0 | | |
| CQGQD9 | 413.0 | | 413.0 | | |
| FMTTH6 | 289.6 | 305.5 | 297.5 | | |
| FZU93A | 373.0 | | 373.0 | | |
| HGDJ63 | 335.7 | | 335.7 | | |
| K6A8M6 | 347.0 | | 347.0 | | |
| KXQ83L | 329.5 | 333.2 | 331.4 | | |
| L67AMT | 302.0 | | 302.0 | | |
| LZEXPC | 334.0 | | 334.0 | | |
| M6MNQW | 407.8 | | 407.8 | | |
| N7E2QU | 409.1 | | 409.1 | | |
| NJ37XQ | 388.5 | 383.5 | 453.5 | 376.0 | 400.4 |

TABLE 2C Item 2
Item 2 Raw Data - MDMA
Preparation concentration: (345 ng/mL)

| Webcode | Raw Data (ng/mL) | | | Participant Mean |
|----------------|-------------------------|-------|-------|-------------------------|
| PB4ZHV | 400.6 | | | 400.6 |
| RUNGZE | 334.0 | | | 334.0 |
| T23MAQ | 284.3 | | | 284.3 |
| V4LDER | 380.0 | | | 380.0 |
| VH3E8C | 330.0 | 350.0 | 320.0 | 333.3 |
| VKUATK | 307.0 | | | 307.0 |
| XBDFRN | 425.5 | | | 425.5 |
| XMQWYK | 408.4 | | | 408.4 |
| YC9F9Y | 332.9 | | | 332.9 |
| YXL4WP | 365.7 | | | 365.7 |

Statistical Analysis for Item 2 - MDMA

| | | | | | |
|--------------------|--------------|---------------------------------|-----------|--|-----------|
| Grand Mean | 353.2 | Number of Participants Included | 38 | Number of Participants without Raw Data or Data that was not reported in ng/mL | 64 |
| Standard Deviation | 45.17 | Number of Participants Excluded | 0 | | |

TABLE 2C Item 2
Item 2 Raw Data - MDA
Preparation concentration: (50 ng/mL)

| Webcode | Raw Data (ng/mL) | | | Participant Mean | |
|---------|------------------|-------|-------|------------------|-------|
| 3RPK4H | 60.61 | | | 60.61 | |
| 4C8ATZ | 43.00 | 50.00 | | 46.50 | |
| 4DHARF | 40.00 | | | 40.00 | |
| 6DZMTX | 43.36 | | | 43.36 | |
| 79YZEZ | 47.00 | | | 47.00 | |
| 7ATPXV | 47.39 | | | 47.39 | |
| 7FH2YJ | 60.00 | | | 60.00 | |
| 7FJ2UC | 68.03 | | | 68.03 | |
| 83RPZE | 49.00 | 43.00 | | 46.00 | |
| 8T34RV | 48.78 | | | 48.78 | |
| 9F8CHB | 64.77 | | | 64.77 | |
| ABG2BX | 42.00 | 42.00 | | 42.00 | |
| AN7YEG | 51.60 | 53.40 | | 52.50 | |
| AQCJ2G | 50.00 | | | 50.00 | |
| BX2N9N | 68.00 | | | 68.00 | |
| CQGQD9 | 55.12 | | | 55.12 | |
| FMTTH6 | 55.87 | 50.16 | | 53.01 | |
| FZU93A | 73.00 | | | 73.00 | |
| K6A8M6 | 71.00 | | | 71.00 | |
| KXQ83L | 52.35 | 57.84 | | 55.09 | |
| L67AMT | 44.00 | | | 44.00 | |
| LZEXPC | 63.00 | | | 63.00 | |
| M6MNQW | 63.73 | | | 63.73 | |
| N7E2QU | 67.21 | | | 67.21 | |
| NJ37XQ | 51.35 | 49.10 | 62.50 | 49.20 | 53.04 |
| PB4ZHV | 61.98 | | | 61.98 | |
| RUNGZE | 49.00 | | | 49.00 | |
| T23MAQ | 50.70 | | | 50.70 | |
| V4LDER | 70.00 | | | 70.00 | |
| VH3E8C | 93.00 | 86.00 | 104.0 | 94.33 | X |
| VKUATK | 46.00 | | | 46.00 | |

TABLE 2C Item 2
Item 2 Raw Data - MDA
Preparation concentration: (50 ng/mL)

| Webcode | Raw Data (ng/mL) | Participant Mean |
|----------------|-------------------------|-------------------------|
| XBDFRN | 64.10 | 64.10 |
| XMQWYK | 64.35 | 64.35 |

Statistical Analysis for Item 2 - MDA

| | | | | | |
|--------------------|--------------|---------------------------------|-----------|--|-----------|
| Grand Mean | 55.91 | Number of Participants Included | 32 | Number of Participants without Raw Data or Data that was not reported in ng/mL | 62 |
| Standard Deviation | 9.699 | Number of Participants Excluded | 1 | | |

TABLE 2C Item 2
Item 2 Raw Data - 11-nor-9-carboxy-delta-9-THC
Preparation concentration: (85 ng/mL)

| Webcode | Raw Data (ng/mL) | | Participant Mean |
|---------|------------------|-------|------------------|
| 2DPLGK | 88.74 | | 88.74 |
| 3RPK4H | 68.57 | | 68.57 |
| 43M3WW | 77.81 | | 77.81 |
| 4C8ATZ | 100.0 | 92.00 | 96.00 |
| 6DZMTX | 72.74 | | 72.74 |
| 79YZEZ | 68.27 | | 68.27 |
| 7AD6BC | 84.26 | | 84.26 |
| 7ATPXV | 88.52 | | 88.52 |
| 7AVDZ8 | 81.24 | | 81.24 |
| 7FH2YJ | 85.00 | | 85.00 |
| 7FJ2UC | 73.66 | | 73.66 |
| 7QGWE | 83.02 | | 83.02 |
| 7ZUQCG | 78.36 | | 78.36 |
| 8T34RV | 79.42 | | 79.42 |
| 8WMTC9 | 85.72 | | 85.72 |
| 9833FR | 70.40 | | 70.40 |
| 9A48TC | 89.22 | | 89.22 |
| 9F8CHB | 82.74 | | 82.74 |
| 9KNGG7 | 93.51 | | 93.51 |
| ALFUG4 | 77.95 | | 77.95 |
| AN7YEG | 87.40 | 82.20 | 84.80 |
| AQCJ2G | 32.00 | | 32.00 X |
| B2MB2B | 85.82 | | 85.82 |
| BGE937 | 91.34 | | 91.34 |
| BHAUVW | 68.60 | | 68.60 |
| BKW9K8 | 91.71 | | 91.71 |
| BM3VXB | 86.17 | | 86.17 |
| BX2N9N | 102.0 | | 102.0 |
| C2JBF2 | 80.38 | | 80.38 |
| CMHCT6 | 90.61 | | 90.61 |
| CQGQD9 | 66.76 | | 66.76 |

TABLE 2C Item 2
Item 2 Raw Data - 11-nor-9-carboxy-delta-9-THC
Preparation concentration: (85 ng/mL)

| Webcode | Raw Data (ng/mL) | Participant Mean |
|---------|------------------|------------------|
| DHM6M2 | 95.76 | 95.76 |
| DPKU9C | 86.15 | 86.15 |
| EJQEWA | 87.44 | 87.44 |
| EV6CW8 | 88.12 | 88.12 |
| F77W47 | 83.44 | 83.44 |
| FMTTH6 | 72.03 | 72.03 |
| FWT6A2 | 83.64 | 83.64 |
| FZU93A | 86.87 | 86.87 |
| HEPCGY | 92.98 | 92.98 |
| HZ9EF6 | 81.12 | 81.12 |
| J7TW97 | 72.00 | 72.00 |
| JNRR2X | 95.56 | 95.56 |
| K6A8M6 | 81.34 | 81.34 |
| L67AMT | 84.00 | 84.00 |
| LZEXPC | 87.00 | 87.00 |
| M6MNPQW | 71.46 | 71.46 |
| MVZKKH | 91.90 | 91.90 |
| N628BU | 86.06 | 86.06 |
| N7E2QU | 83.72 | 83.72 |
| PB4ZHV | 79.95 | 79.95 |
| R4GR9N | 96.25 | 96.25 |
| RA2RQM | 101.2 | 101.2 |
| RNNZNN | 83.91 | 83.91 |
| RUNGZE | 75.18 | 75.18 |
| T23MAQ | 78.70 | 78.70 |
| T7FKJY | 63.48 60.90 | 62.19 |
| TC3B7U | 80.93 | 80.93 |
| UV969K | 87.04 | 87.04 |
| UVVBV6 | 85.72 | 85.72 |
| UYA7X | 75.50 | 75.50 |

TABLE 2C Item 2
Item 2 Raw Data - 11-nor-9-carboxy-delta-9-THC
Preparation concentration: (85 ng/mL)

| Webcode | Raw Data (ng/mL) | Participant Mean | |
|----------------|-------------------------|-------------------------|---|
| V4LDER | 88.00 | 88.00 | |
| VKUATK | 80.00 | 80.00 | |
| W34NNK | 90.56 | 90.56 | |
| WFW7GR | 57.38 | 57.38 | |
| WYNJPP | 89.00 | 89.00 | |
| XBDFRN | 67.73 | 67.73 | |
| XMQWYK | 76.14 | 76.14 | |
| YC9F9Y | 241.0 | 241.0 | X |
| YXL4WP | 43.81 | 43.81 | X |

Statistical Analysis for Item 2 - 11-nor-9-carboxy-delta-9-THC

| | | | | | |
|--------------------|--------------|---------------------------------|-----------|--|-----------|
| Grand Mean | 82.68 | Number of Participants Included | 67 | Number of Participants without Raw Data or Data that was not reported in ng/mL | 16 |
| Standard Deviation | 9.107 | Number of Participants Excluded | 3 | | |

TABLE 2C Item 2
Item 2 Raw Data - Other

| Webcode | Raw Data (ng/mL) | Participant Mean |
|---------|----------------------------|------------------|
| N87Z6T | [No analyte name reported] | 51.744 |

Statistical Analysis for Item 2 - Other

Please note statistical analysis is not provided for other drug responses.

Reporting Procedures - Item 2

If quantitative analysis was performed, the reported concentrations are:

TABLE 2D Item 2

| Webcode | Quantitative Reporting Procedures |
|---------|---|
| 2DPLGK | A single determination. |
| 2RDN2X | A single determination. |
| 3RPK4H | A single determination. |
| 43M3WW | A single determination. |
| 4C8ATZ | The mean of duplicate/several determinations. |
| 4DHARF | A single determination. |
| 6DZMTX | A single determination. |
| 79YZEZ | A single determination. |
| 7AD6BC | A single determination. |
| 7ATPXV | A single determination. |
| 7AVDZ8 | A single determination. |
| 7FH2YJ | A single determination. |
| 7FJ2UC | A single determination. |
| 7QGWWE | A single determination. |
| 7ZUQCG | A single determination. |
| 8NAYYQ | A single determination. |
| 8T34RV | A single determination. |
| 8WMTC9 | A single determination. |
| 9833FR | A single determination. |
| 9A48TC | A single determination. |
| 9F8CHB | A single determination. |
| 9KNGG7 | A single determination. |
| ABG2BX | The mean of duplicate/several determinations. |
| ALFUG4 | A single determination. |
| AN7YEG | The mean of duplicate/several determinations. |
| AQCJ2G | A single determination. |
| B2MB2B | A single determination. |
| BGE937 | A single determination. |
| BHAUVW | A single determination. |

TABLE 2D Item 2

| Webcode | Quantitative Reporting Procedures |
|---------|---|
| BKW9K8 | A single determination. |
| BM3VXB | A single determination. |
| BX2N9N | A single determination. |
| C2JBF2 | A single determination. |
| CMHCT6 | A single determination. |
| CQGQD9 | A single determination. |
| DHM6M2 | A single determination. |
| DPKU9C | A single determination. |
| EJQEWA | A single determination. |
| EV6CW8 | A single determination. |
| F77W47 | A single determination. |
| FMTHH6 | A single determination. |
| FWT6A2 | A single determination. |
| FZU93A | A single determination. |
| HEPCGY | A single determination. |
| HGDJ63 | The mean of duplicate/several determinations. |
| HZ9EF6 | A single determination. |
| J7TW97 | A single determination. |
| JD9D32 | A single determination. |
| JNRR2X | A single determination. |
| K6A8M6 | A single determination. |
| L67AMT | A single determination. |
| LZEXPC | A single determination. |
| M6MNQW | A single determination. |
| MVZKKH | A single determination. |
| N628BU | A single determination. |
| N7E2QU | A single determination. |
| N87Z6T | A single determination. |
| NJ37XQ | The mean of duplicate/several determinations. |
| PB4ZHV | A single determination. |
| R4GR9N | A single determination. |
| RA2RQM | A single determination. |

TABLE 2D Item 2

| Webcode | Quantitative Reporting Procedures |
|----------------|---|
| RNNZNN | A single determination. |
| RUNGZE | A single determination. |
| T23MAQ | A single determination. |
| T7FKJY | The mean of duplicate/several determinations. |
| TC3B7U | A single determination. |
| UV969K | A single determination. |
| UVVBV6 | A single determination. |
| UYA7X | A single determination. |
| V4LDER | A single determination. |
| VH3E8C | The mean of duplicate/several determinations. |
| VKUATK | A single determination. |
| W34NNK | A single determination. |
| WFW7GR | A single determination. |
| WYNJPP | A single determination. |
| XBDFRN | A single determination. |
| XMQWYK | A single determination. |
| YC9F9Y | A single determination. |
| YXL4WP | A single determination. |

| Response Summary for Item 2 | | Participants: 79 |
|---|------------|-------------------------|
| A single determination: | 72 (91.1%) | |
| The mean of duplicate/several determinations: | 7 (8.9%) | |

Method of Analysis - Item 2

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|--------------|-----------|--------------|--------------|
| 2DPLGK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| 2RDN2X | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 3RPK4H | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| 43M3WW | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| 46BFXM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 4C8ATZ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | | ✓ | ✓ |
| | UPLC QTOF MS | ✓ | | |
| 4DHARF | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | | ✓ | |
| 4ZHB6H | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 6DZMTX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 6FM2LE | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| 79YZEZ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| 7AD6BC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| 7ATPXV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 7AVDZ8 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| 7FH2YJ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | | ✓ |
| 7FJ2UC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| 7QGWE | Immunoassay | ✓ | | |
| | LC/MS | | ✓ | |
| | GC/MS | | ✓ | |
| 7ZUQCG | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 83RPZE | GC/MS | ✓ | | |
| | LC-TOF | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 8NAYYQ | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 8T34RV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 8WMT9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| 9833FR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 9A48TC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| 9ANN9F | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9F8CHB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| 9JVLUX | Immunoassay | ✓ | | |
| 9KNGG7 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | | ✓ |
| 9LKREU | Immunoassay | ✓ | | |
| ABG2BX | Immunoassay | ✓ | | |
| | LC/MS/MS | | | ✓ |
| | LC/QTOF | ✓ | | |
| | HPLC-DAD | ✓ | | |

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| AHDRV9 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| ALFUG4 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| AN7YEG | LC/MS/MS | ✓ | ✓ | ✓ |
| AQCJ2G | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| AWFMRF | GC/MS | ✓ | ✓ | |
| AYHL39 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| B2MB2B | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| B2MB6G | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| BBDW79 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| BF499W | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| | GC/MS/MS/MS | | ✓ | |
| BGE937 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| BHAUVW | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | | ✓ |
| BKW9K8 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| BM3VXB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| BX2N9N | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| C2JBF2 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| CKVX4U | Immunoassay | ✓ | | |
| CMHCT6 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC\FID | | ✓ | |
| CQGQD9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| DAVJLA | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |
| DHM6M2 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| DPKU9C | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| EJQEWA | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| EQXLY8 | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| EV6CW8 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| F77W47 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | | ✓ |
| FHXQA8 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| FMTTH6 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| FWT6A2 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | ✓ |
| | GC/FID | | ✓ | |
| FZU93A | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC-FID | | | ✓ |
| GGJE9H | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| GX72E7 | LC/MS/MS | ✓ | ✓ | |
| H9ZU49 | LC/MS/MS | ✓ | | |
| HEPCGY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | |
| HGDJ63 | LC/MS | ✓ | | ✓ |
| | LC/MS/MS | | ✓ | |
| HZ9EF6 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| J6E88E | Immunoassay | ✓ | | |

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|--|-------------|--------------|--------------|
| J7TW97 | Immunoassay GC/MS | ✓ | ✓ | ✓ |
| J7UKXW | Immunoassay GC/MS LC/MS | ✓ | ✓ ✓ | |
| JD9D32 | LC/MS/MS | ✓ | ✓ | ✓ |
| JNRR2X | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| K6A8M6 | Immunoassay GC/MS GC-FID | ✓ | ✓ | ✓ ✓ |
| KL6674 | Immunoassay | ✓ | | |
| KXE9AX | LC/MS/MS | ✓ | | |
| KXQ83L | Immunoassay GC/MS LC/MS/MS QTOF | ✓ ✓ ✓ | ✓ | ✓ |
| L67AMT | Immunoassay GC/MS | ✓ | ✓ | ✓ |
| LZEXPC | Immunoassay LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| M6M9QW | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | |
| MVZKKH | Immunoassay GC/MS GC/MS/MS | ✓ | ✓ ✓ | ✓ ✓ |
| MW9UE2 | Immunoassay GC/MS | ✓ | ✓ | |
| N628BU | Immunoassay GC/MS GC-FID | ✓ | ✓ ✓ | ✓ |
| N7E2QU | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | ✓ ✓ |
| N87Z6T | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| NJ37XQ | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| PATW9D | GC/MS LC/MS/MS | ✓ | ✓ | |

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| PB4ZHV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| R2PQAR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| R4GR9N | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| RA2RQM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| RNNZNN | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| RUNGZE | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| T23MAQ | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| T7FKJY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | | ✓ |
| TC3B7U | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| TD3DVX | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TTCYGA | LC/MS/MS | ✓ | ✓ | |
| U9HM6U | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| UV969K | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| UVVBV6 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | ✓ |
| UXY93R | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| UYA7X | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | ✓ |
| V4LDER | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | | ✓ |
| VH3E8C | LC/MS/MS | ✓ | | ✓ |

TABLE 2E Item 2

| Webcode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| VKUATK | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |
| VMDMCM | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| VNVBXN | LC/MS/MS | ✓ | ✓ | |
| W34NNK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC-FID | | ✓ | |
| WFW7GR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC/FID | | ✓ | |
| WYNJPP | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| XBDFRN | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| XMQWYK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | ✓ | ✓ |
| YC9F9Y | LC/MS/MS | ✓ | ✓ | ✓ |
| YXL4WP | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |

| Response Summary for Item 2 | | Participants: 113 | | |
|-----------------------------|-----------|-------------------|--------------|--|
| | Screening | Confirmatory | Quantitation | |
| Immunoassay: | 99 | 0 | 0 | |
| GC/MS: | 20 | 79 | 37 | |
| LC/MS: | 1 | 2 | 1 | |
| LC/MS/MS: | 23 | 54 | 43 | |
| Other: | 8 | 18 | 6 | |

Additional Comments for Item 2

TABLE 2F Item 2

| Webcode | Item 2 - Comments |
|---------|--|
| 4C8ATZ | 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxyamphetamine Qualitative Analysis: Instrument: GC/MS with Electron Impact (EI) ionisation (AGILENT). Method: Derivatized with Heptafluorobutyric anhydride (HFBA) and then analysed by Quadrupole GC-MS in SIM mode. Internal Standards: D5-3,4-Methylenedioxyamphetamine and D5-3,4-Methylenedioxyamphetamine. LOD: 3,4-MDA and 3,4-MDMA = 10 ng/mL. Delta-9-THC Acid Qualitative Analysis: Instrument: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) in Multiple Reaction Monitoring (MRM) mode. Method: Sample is buffered and extracted with a hexane / ethyl acetate solvent mixture. Internal Standards: D3-THC and D3-THC Acid. LOD: 0.5 ng/mL |
| 4DHARF | 11-nor-Delta-9-Carboxy-THC: Internal standards used were D3-THC and D3-THC-COOH. Limit of detection is 1.0 ng/mL. MDA/MDMA: Internal standards used were D5-Amphetamine, D5-Methamphetamine, D5-MDA, and D5-MDMA. Limit of detection is 30 ng/mL. |
| 6DZMTX | amphetamines: MDA internal standard = MDA-d5, MDMA internal standard = MDMA-d5; LOQ = 10 ng/mL. 11-nor-9-carboxy-delta9-THC internal standard = 11-nor-9-carboxy-delta9-THC-d3; LOQ = 5 ng/mL |
| 79YZEZ | Immunoassay analyte: cutoff - Amphetamine: 20 ng/mL, Methamphetamine: 20 ng/mL, Morphine: 20 ng/mL, Benzoylcegonine: 50 ng/mL, Oxazepam 50 ng/mL, Carboxytetrahydrocannabinol 20 ng/mL |
| 7AD6BC | IS = THC-COOH D3. LOQ = 15 ng/mL. IS=Mepivacaine |
| 7ATPXV | amphetamines: MDA internal standard = MDA-d5, MDMA internal standard = MDMA-d5; LOQ = 10 ng/mL. 11-nor-9-carboxy-delta9-THC internal standard = 11-nor-9-carboxy-delta9-THC-d3; LOQ = 5 ng/mL |
| 7AVDZ8 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone, phencyclidine, and zolpidem. Confirmation/quantitation for delta-9-tetrahydrocannabinol (d-9-THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (carboxy-THC) following positive cannabinoid screen. d-9-THC-D3 and carboxy-THC-D3 used as internal standards. LOQ/LOD is 1 ng/mL for d-9-THC and 5 ng/mL for carboxy-THC. d-9-THC was not detected. Confirmation/quantitation for amphetamine following positive screen. Amphetamine-D5 used as internal standard. LOQ/LOD is 4 ng/mL for amphetamine. Amphetamine was not detected. |
| 7FJ2UC | mepivacaine, THC-COOH-d9 |
| 7QGWWE | Internal Standard: Mepivacaine (BSPE), Amphetamine D-11 Acetyl (PHEALLE), Methamphetamine D-11 Acetyl (PHEALLE), THC-D3 (BCLLE), 11-OH-THC-D3 (BCLLE), THCA-D3 (BCLLE) |
| 7ZUQCG | Internal standards used: Mepivacaine, Nalorphine, THC-D3, 11-OH-THC-D3, THCA-D3, Amphetamine-D11, Methamphetamine-D11. Hydroxyzine related peak indicated: Not reported, no standard available for comparison. THCA Limits of detection: LLOD-5ng/mL, ULOD-500ng/mL |
| 83RPZE | Internal standard: MDMA-D5, LOD: 6.25 ng/mL, LOQ: 12.5 ng/mL. Internal standard: MDA-D5, LOD: 6.25 ng/mL, LOQ: 12.5 ng/mL |
| 8NAYYQ | MDA LOD=25ng/mL, LOQ=50ng/mL |
| 8T34RV | amphetamines: MDA internal standard = MDA-d5, MDMA internal standard = MDMA-d5; LOQ = 10 ng/mL. 11-nor-9-carboxy-delta9-THC internal standard = 11-nor-9-carboxy-delta9-THC-d3; LOQ = 5 ng/mL |
| 8WMTC9 | Methamphetamine-D11 internal standard used in the detection of MDA and MDMA. THCA-D3 internal standard used in the detection of THCA. |

TABLE 2F Item 2

| Webcode | Item 2 - Comments |
|---------|---|
| 9ANN9F | Preliminary testing indicated the possible presence of a cannabinoid class compound, confirmatory testing not pursued because analyst is not trained in the cannabinoid analytical method. |
| 9F8CHB | 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) used the internal standard mepivacaine in order to quantitate. The limit of detection for MDA and MDMA is 12.5 mcg/L. 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid used the internal standard THC-COOH d9 to quantitate. The limit of detection is 5 ng/mL. |
| 9KNGG7 | MDA & MDMA are only called positive and not quantitated on GC/FID. THC-COOH is confirmed/quantitated on GC/MS |
| ABG2BX | D5-MDMA & D5-MDA used as ISTDs. LOR = 0.01mg/L. LOD = 0.005mg/L. |
| AHDRV9 | Butyl Acetate Screen - Promazine (IStd) |
| ALFUG4 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone. 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (carboxy-THC) Carboxy-THC-D3 used as internal standards. LOQ/LOD is 5 ng/mL for Carboxy-THC |
| BBDW79 | Cannabinoids were not confirmed because [Laboratory] does not confirm cannabinoids in-house. In casework, samples would be sent out for confirmation. |
| BF499W | LC/MS/MS/MS instead of LC/MS/MS used for confirmatory method. Option not available on drop down to select LC/MS/MS/MS. |
| BKW9K8 | Internal Standard= Mepivacaine. Internal Standard= THC-COOH-D3, LOQ= 15 ng/mL. Note: It is our policy to call MDA and MDMA positive only. We do not quantitate those drugs. U of M for THC-COOH= 13.06% at 95.45% (see above calculated range [Table 2B - Confirmatory Results-Item 2]) |
| BM3VXB | GCMS analysis: Internal standard: Mepivacaine, Amphetamine D-11 acetyl, Methamphetamine D-11 acetyl. LCMSMS: Internal standard: THC D-3; 11-OH-THC-D3; THCA-D3. |
| BX2N9N | Internal standard is MDMA-D5 and Carboxy THC-D9. Limit of detection is 10ng/mL and 2ng/mL respectively |
| C2JBF2 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone, phencyclidine, and zolpidem. Carboxy-THC-D3 used as internal standard. LOQ/LOD for carboxy-THC is 5ng/ml. |
| CKVX4U | The sample was screened for the following type/class of drugs: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, PCP. No confirmatory method was used on this sample since that is beyond my current qualifications. |
| CMHCT6 | The lab does not quantitate MDMA or MDA. |
| CQGQD9 | THC-COOH internal standard-THC-COOH-d9. MDA and MDMA internal standard-mepivacaine |
| DHM6M2 | MDA + MDMA are not quantitated using our basic extraction. They are only identified as positive. |
| DPKU9C | We do not currently test for parent THC. |
| EJQEWA | GC-MS was used to quantitate 11-nor-9-carboxy-delta-9-THC (SIM mode). GC-FID was used for MDMA and MDA (for these analytes, it was qualitative only). |
| EQXLY8 | MDMA CONFIRMATORY: limit of detection is 50 ng/mL.(LC/MS/MS). Tetrahydrocannabinol-9-carboxylic acid CONFIRMATORY: limit of detection is 10ng/mL (GC/MS) |
| EV6CW8 | Internal Standard (GCMS): Mepivacaine. Internal Standard (LC/MS/MS) THC-D3, 11-OH-THC-D3, THCA-D3 |

TABLE 2F Item 2

| Webcode | Item 2 - Comments |
|---------|---|
| F77W47 | Internal Standards used: Mepivacaine, Amphetamine D-11 Acetyl, Methamphetamine D-11 Acetyl, Tetrahydrocannabinol D-3, 11-hydroxy-delta-9-tetrahydrocannabinol D-3, and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid D-3. MDA Limit of Detection: 12.5 ng/mL. MDMA Limit of Detection: 12.5 ng/mL. THCA Lower Limit of Quantitation: 5 ng/mL |
| FHXA8 | Caffeine was also confirmed in the blood sample. The drug was not reported independently in sections 2-1 [Table 2A - Screening Results-Item 2] and 2-2 [Table 2B - Confirmatory Results-Item 2] because it was confirmed in all three PT samples. |
| FWT6A2 | Expanded uncertainty - 95.42%, K=2 (THC-COOH 13.06 %) |
| HEPCGY | expanded uncertainty - 95.42%, k=2 (13.06) |
| HGDJ63 | Internal Standard = Estazolam (1000 ng/mL) |
| HZ9EF6 | GC/MS Internal standard (base extraction): Mepivacaine. GC/MS Internal standard (phenethylamine extraction): Amphetamine-D11 and Methamphetamine-D11. LC/MS/MS Internal standard: THC-D3, 11-OH-THC-D3, THCA-D3 |
| JD9D32 | LOD = 10 ng/mL. Linearity = 25 - 300 ng/mL. Internal Standard = Flurazepam |
| JNRR2X | Internal standard used is mepivacaine. Internal standard used is thc-cooh-d3. LOQ is 15ng/ml. We only call MDA and MDMA positive. Measurement of certainty for thc-cooh is calculated at 13.06% certainty at a 95.45% confidence level. Please see above for the calculated range [Table 2B - Confirmatory Results-Item 2]. |
| KLG674 | Cutoff concentration for cannabinoids assay: 5 ng/mL. Cutoff concentration for methamphetamine assay: 20 ng/mL |
| KXE9AX | MDA was identified by a very low signal (concentration). The laboratory does not have enough tools to quantify it so it could be possible that MDA was a degradation product from de MDMA. Internal Standard = Estazolam |
| L67AMT | 11-nor-9-carboxy-delta-9-THC: Internal Standard: d9-11-nor-9-carboxy-delta-9-THC: LOD: 2 ng/mL, LOQ: 2 ng/mL. 3,4-Methylenedioxyamphetamine (MDA): Internal Standard: d5-3,4-Methylenedioxyamphetamine, LOD: 25 ng/mL, LOQ: 25 ng/mL. 3,4-Methylenedioxymethamphetamine (MDMA): Internal Standard: d5-3,4-Methylenedioxymethamphetamine, LOD: 25 ng/mL, LOQ: 25 ng/mL |
| LZEXPC | Internal standard is MDMA-D5 and Carboxy THC-D9. Limit of detection is 10 ng/mL and 2 ng/mL respectively |
| M6MNQW | IS: THC-COOH d9, mepivacaine. LOD: THC-COOH (5 ng/mL), MDMA/MDA (12.5 µg/L) |
| MVZKKH | The compounds that were analyzed using the GC/MS method were Methamphetamine and Amphetamine. Both of these compounds were none detected. Internal standards used were Methamphetamine-D14 and Amphetamine-D11 with a cut off of 25 ng/mL. The compounds that were analyzed using the GC/MS/MS method were THC, OH-THC, and THCA. Both THC and OH-THC were none detected and THCA was positive. Internal standards used were THC-D3, OH-THC-D3 and THCA-D9 with a cut off of 0.5 ng/mL for THC and OH-THC and 5 ng/mL THCA. |
| MW9UE2 | [Laboratory] does not routinely perform confirmatory testing for THC in blood. |
| N7E2QU | THC-COOH d9 used as internal standard. Mepivacaine used as internal standard for MDMA and MDA. |
| N87Z6T | The lab does not quantitate MDMA and MDA. |
| NJ37XQ | Positive cannabinoids from positive ELISA screen only. LOQ for both MDMA, MDA is 10 ng/mL. Internal standards MDMA-D5, MDA-D5. Used quantitation data from 8/23/17 only. |

TABLE 2F Item 2

| Webcode | Item 2 - Comments |
|---------|--|
| PATW9D | Used Internal standards: For the screening: Phenobarbital D-5. For MDA and MDMA Confirmatory: Codeine D-3 was used. For 11-nor-9-carboxy- delta-9-THC- Confirmatory: 11-nor-9-carboxy- delta-9-THC-D3 was used |
| PB4ZHV | Internal standards used: mepivacaine and deuterated THC-COOH |
| R4GR9N | I.S. = mepivacaine, d3-THC-COOH. Measurement certainty calculated at 13.06% with a 95.45% confidence interval |
| RNNZNN | Internal standards: Mepivacaine, Amphetamine-D11, Methamphetamine-D11, THC-D3, 11-OH-THC-D3, THCA-D3 LOD: MDA - 12.5 ng/ml MDMA - 12.5 ng/ml LLOQ: THCA - 5 ng/ml |
| RUNGZE | Screen for following w/ cut-off values: Amp 20ng/ml, Oxa 50ng/ml, BE 50ng/ml, Meth 20ng/ml, Morphine 20ng/ml, C-THC 20ng/ml. Confirm negative for Meth, Amp, delta9 THC, OH-THC. |
| T23MAQ | Internal standards - THC-COO-D9, MDMA-D5, MDA-D5. THC-COO LOD 5ng/mL, MDMA LOD 10ng/mL, MDA LOD 10ng/mL. |
| TC3B7U | Internal Standards: Mepivacaine, Amphetamine D-11 acetyl, Methamphetamine D-11 acetyl, delta-9-tetrahydrocannabinol (delta-9-THC)-D3, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA)-D3, 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC)-D3. LLOQ/ULOQ for THC: 1.00/100.00 ng/ml. LLOQ/ULOQ for 11-OH-THC: 1.00/100.00 ng/ml. LLOQ/ULOQ for THCA: 5.00/500.00 ng/ml |
| U9HM6U | Internal Standard - n-propylamphetamine @ 500 ng/mL (Full Scan). Internal Standard - D3-THC & D3-THC-COOH @ 20 ng/mL (SIM) |
| UV969K | Internal Standards used: Mepivacaine. Amphetamine D-11, Methamphetamine D-11. THC-D3, 11-OH-THC-D3, THCA-D3. LODs: MDA 12.5ng/mL, MDMA 12.5ng/mL, THCA 5ng/mL |
| VH3E8C | MDMA-d5 as internal standard. MDMA LOD: 3 ng/mL. MDA LOD: <1 ng/mL |
| VKUATK | deuterated internal standards |
| VMDMCM | Butyl Acetate screen utilized Promazine internal standard. |
| WFW7GR | The Lab does not quantitate MDMA or MDA. |
| XBDFRN | internal standards: mepivacaine, THC-COOH-d9 |
| XMQWYK | Internal standards: mepivacaine, amphetamine-d11, methamphetamine-d11, delta 9-THC-d3, THCOH-d3, THCA-d9 |

Screening Results - Item 3

TABLE 3A Item 3

Item Scenario:

A 35 year old male was pulled over by police after running a red light. He displayed drowsiness, slurred speech, and confusion. A breath alcohol test resulted in 0.00 percent. A blood sample was collected 1 hour later.

Item Contents and Preparation Concentration: Oxycodone (150 ng/mL)
Noroxycodone (35 ng/mL)

| Webcode | Screening Results |
|---------|---|
| 2DPLGK | Oxycodone/Oxymorphone |
| 2RDN2X | Oxycodone |
| 3RPK4H | oxycodone |
| 43M3WW | Oxycodone/Oxymorphone |
| 46BFXM | Oxycodone |
| 4C8ATZ | Oxycodone |
| 4DHARF | Opiates (Codeine, Morphine, Hydrocodone, & Hydromorphone) |
| 4ZHB6H | No drugs/metabolites detected |
| 6DZMTX | opiates; oxycodone |
| 6FM2LE | Opiates: Oxycodone |
| 79YZEZ | No drugs/metabolites detected |
| 7AD6BC | Opiates |
| 7ATPXV | opiates; oxycodone |
| 7AVDZ8 | Oxycodone, amphetamine |
| 7FH2YJ | Opiates |
| 7FJ2UC | oxycodone |
| 7QGWE | Methadone, Oxycodone |
| 7ZUQCG | Oxycodone/Oxymorphone |
| 83RPZE | Oxycodone |
| 8NAYYQ | Oxycodone |
| 8T34RV | opiates; oxycodone |
| 8WMT9 | Oxycodone/Oxymorphone |
| 9833FR | Oxycodone/Oxymorphone |
| 9A48TC | Oxycodone/Oxymorphone |
| 9ANN9F | Opiates |
| 9F8CHB | Oxycodone and Zolpidem |

TABLE 3A Item 3

| Webcode | Screening Results |
|---------|-----------------------------------|
| 9JVLUX | No drugs/metabolites detected |
| 9KNGG7 | opiates |
| 9LKREU | Oxycodone/ Oxymorphone |
| ABG2BX | Oxycodone |
| AHDRV9 | Oxycodone |
| ALFUG4 | oxycodone |
| AN7YEG | Oxycodone (opioids) |
| AQCJ2G | No drugs/metabolites detected |
| AYHL39 | Oxycodone |
| B2MB2B | Oxycodone/Oxymorphone |
| B2MB6G | Oxycodone |
| BBDW79 | Opiates |
| BF499W | Oxycodones |
| BGE937 | Opiates |
| BHAUVW | Oxycodone 1, Oxycodone 2, Opioids |
| BKW9K8 | opiates |
| BM3VXB | Oxycodone/Oxymorphone |
| BX2N9N | Oxycodone, Noroxycodone |
| C2JBF2 | Oxycodone |
| CKVX4U | No drugs/metabolites detected |
| CMHCT6 | Opiates |
| CQGQD9 | Oxycodone |
| DAVJLA | Oxycodone |
| DHM6M2 | Opiates |
| DPKU9C | Opiates |
| EJQEWA | Opiates presumptively positive. |
| EQXLY8 | No drugs/metabolites detected |
| EV6CW8 | Oxycodone/Oxymorphone |
| F77W47 | Oxycodone/Oxymorphone |
| FHXQA8 | oxycodone |
| FMTTH6 | Oxycodone |

TABLE 3A Item 3

| Webcode | Screening Results |
|----------------|-------------------------------|
| FWT6A2 | Opiate (ELISA) |
| FZU93A | opiates |
| GGJE9H | Opiates |
| GX72E7 | oxycodone, noroxycodone |
| H9ZU49 | Oxycodone |
| HEPCGY | opiate ELISA screen |
| HGDJ63 | Oxycodone |
| HZ9EF6 | Oxycodone/Oxymorphone |
| J6E88E | No drugs/metabolites detected |
| J7TW97 | Oxycodone |
| J7UKXW | No drugs/metabolites detected |
| JD9D32 | Oxycodone |
| JNRR2X | Opiates |
| K6A8M6 | Opiates |
| KL6674 | Oxycodone |
| KXE9AX | Oxycodone |
| KXQ83L | Oxycodone |
| L67AMT | Oxycodone |
| L68ZVW | Opium Derivatives |
| LZEXPC | Oxycodone, Noroxycodone |
| M6MNQW | oxycodone |
| MVZKHH | No drugs/metabolites detected |
| MW9UE2 | No drugs/metabolites detected |
| N628BU | Opiates |
| N7E2QU | No drugs/metabolites detected |
| N87Z6T | Opiates |
| NJ37XQ | Opiate, Oxycodone |
| PATW9D | Oxycodone |
| PB4ZHV | Oxycodone |
| R2PQAR | No drugs/metabolites detected |
| R4GR9N | Opiates |

TABLE 3A Item 3

| Webcode | Screening Results |
|---------|---|
| RA2RQM | Opiates |
| RNNZNN | Oxycodone/Oxymorphone |
| RUNGZE | No drugs/metabolites detected |
| T23MAQ | Oxycodone and Opiates |
| T7FKJY | Opiates and Oxycodone |
| TC3B7U | Oxycodone/Oxymorphone |
| TD3DVX | Oxycodone |
| TTCYGA | Oxycodone |
| U9HM6U | No drugs/metabolites detected |
| UV969K | Oxycodone/Oxymorphone |
| UVBV6 | Oxycodone/Oxymorphone |
| UXY93R | No drugs/metabolites detected |
| UYA7X | Opiate was detected below the screening cut-off |
| V4LDER | Opiate |
| VH3E8C | oxycodone |
| VKUATK | Oxycodone |
| VMDMCM | Opiates |
| VNVBXN | Oxycodone |
| W34NNK | Opiates |
| WFW7GR | Opiates |
| WYNJPP | Oxycodone |
| XBDFRN | oxycodone |
| XMQWYK | Oxycodone |
| YC9F9Y | No drugs/metabolites detected |
| YXL4WP | Oxycodone |

| Response Summary for Item 3 | Participants: 113 |
|--|-------------------|
| Opiates, oxycodone and/or noroxycodone: | 97 |
| Other: | 4 |
| No drugs/metabolites detected: | 16 |
| <p>Totals may add up to more than the total number of participants because participants can report multiple drugs/analytes.</p> | |

Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?

TABLE 3B Item 3

Item Scenario:

A 35 year old male was pulled over by police after running a red light. He displayed drowsiness, slurred speech, and confusion. A breath alcohol test resulted in 0.00 percent. A blood sample was collected 1 hour later.

Item Contents and Preparation Concentration: Oxycodone (150 ng/mL)
Noroxycodone (35 ng/mL)

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| 2DPLGK | Oxycodone | ✓ | | | |
| 2RDN2X | Oxycodone | ✓ | | | |
| 3RPK4H | oxycodone` | | 180 | 50 | mcg/L |
| 43M3WW | Oxycodone | ✓ | | | |
| 46BFXM | Oxycodone | | 150 ug/l | 33% | ug/l |
| 4C8ATZ | Oxycodone | | 150 | 30 | ng/mL |
| 4DHARF | Oxycodone, Total | | 130 | 20% | ng/mL |
| 4ZHB6H | Oxycodone | ✓ | | | |
| 6DZMTX | oxycodone | | 140 | 25 | ng/mL |
| 6FM2LE | Oxycodone | | | | |
| 7AD6BC | Oxycodone | | 0.11 | +/- 0.02 | ug/mL |
| 7ATPXV | oxycodone | | 120 | 21 | ng/mL |
| 7AVDZ8 | Oxycodone | | 0.13 | ± 0.03 | µg/mL |
| 7FH2YJ | Oxycodone | | 0.15 | +/-0.03 | ug/ml |
| 7FJ2UC | oxycodone | | 0.14 | +/- 0.04 | mg/L |
| 7QGWE | Oxycodone | ✓ | | | |
| 7ZUQCG | Oxycodone | ✓ | | | |
| 83RPZE | Oxycodone | | 0.13 | 0.02 | mg/L |
| 8NAYYQ | Oxycodone | | 140 | | ng/mL |
| 8T34RV | oxycodone | | 130 | 21 | ng/mL |
| 8WMTc9 | Oxycodone | ✓ | | | |

TABLE 3B Item 3

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| 9833FR | Oxycodone | ✓ | | | |
| 9A48TC | Oxycodone | ✓ | | | |
| | Noroxycodone | ✓ | | | |
| 9ANN9F | Oxycodone | ✓ | | | |
| 9F8CHB | Oxycodone | | 0.15 | +/- 0.04 | mg/L |
| 9KNGG7 | oxycodone | | 0.10 | +/- .02 | ug/mL |
| ABG2BX | Oxycodone | | 0.12 | ±0.012 | mg/L |
| AHDRV9 | Oxycodone | ✓ | | | |
| ALFUG4 | oxycodone | | 0.14 | 0.03 | ug/mL |
| AN7YEG | Oxycodone | | 176.3 | ±16.4% | ng/mL |
| AYHL39 | Oxycodone | ✓ | | | |
| B2MB2B | Oxycodone | ✓ | | | |
| B2MB6G | Oxycodone | | 170 | 53 | ug/mL |
| BBDW79 | Oxycodone | ✓ | | | |
| BGE937 | Oxycodone | | 0.13 | +/- 0.02 | ug/mL |
| BHAUVW | Oxycodone | | 140 | | ng/mL |
| BKW9K8 | oxycodone | | 0.14 | (0.12-0.17) | ug/mL |
| BM3VXB | Oxycodone | ✓ | | | |
| BX2N9N | Oxycodone | | 165 | 14 | ng/mL |
| | Noroxycodone | ✓ | | | |
| C2JBF2 | oxycodone | | 0.14 | ±0.03 | µg/ml |
| CMHCT6 | Oxycodone | | 0.11 | +/- 0.02 | ug/mL |
| CQGQD9 | Oxycodone | | 0.13 | +/-0.03 | mg/L |
| DAVJLA | Oxycodone | ✓ | | | |
| DHM6M2 | Oxycodone | | 0.12 | +/- 0.02 | ug/mL |
| DPKU9C | Oxycodone | | 0.13 | +/-0.02 | ug/ml |
| EJQEWA | Oxycodone | | 0.14 | +/- 0.03 | ug/mL |
| EQXLY8 | OXYCODONE | ✓ | | | |

TABLE 3B Item 3

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| EV6CW8 | Oxycodone | ✓ | | | |
| F77W47 | Oxycodone | ✓ | | | |
| FHXQA8 | oxycodone | ✓ | | | |
| FMTHH6 | Oxycodone | | 108 | 32.4 | ng/mL |
| FWT6A2 | Oxycodone | | 0.10 | | ug/ml |
| FZU93A | oxycodone | | 0.13 | 0.02 | ug/ml |
| GGJE9H | Oxycodone | ✓ | | | |
| GX72E7 | Oxycodone | ✓ | | | |
| | Noroxycodone | ✓ | | | |
| HEPCGY | oxycodone | | 0.11 | 0.09-0.13 | ug/mL |
| HGDJ63 | Oxycodone | | 138.5 ng/mL | 4.0 | ng/mL |
| HZ9EF6 | Oxycodone | ✓ | | | |
| J7TW97 | Oxycodone | | 137 | | ng/mL |
| J7UKXW | Oxycodone | ✓ | | | |
| JD9D32 | Oxycodone | | 170 ng/mL | 0.06 | ng/mL |
| JNRR2X | oxycodone | | 0.14 | .12-.17 | ug/ml |
| K6A8M6 | Oxycodone | | 0.15 | +/-0.03 | ug/ml |
| KL6674 | Oxycodone | ✓ | | | |
| KXE9AX | Oxycodone | ✓ | | | |
| KXQ83L | oxycodone | | 0.13 | 0.01 | mg/L |
| L67AMT | Oxycodone | | 148 | 30 | ng/mL |
| L68ZVW | Oxycodone | ✓ | | | |
| LZEXPC | Oxycodone | | 159 | 14 | ng/mL |
| | Noroxycodone | ✓ | | | |
| M6MNPQW | oxycodone | | 0.13 | 0.03 | mg/L |
| MW9UE2 | 3,4-MDMA | ✓ | | | |
| N628BU | Oxycodone | | 0.10 | 0.09 - 0.12 | ug/ml |
| N7E2QU | oxycodone | | 99 | 25 | mcc/L |

TABLE 3B Item 3

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|------------------|------------------|------------------------|-------------|-------|
| N87Z6T | Oxycodone | | 0.10 | +/- 0.02 | ug/mL |
| NJ37XQ | Oxycodone | | 0.16 | 0.03 | mg/L |
| | Noroxycodone | | 0.042 | 0.006 | mg/L |
| PATW9D | oxycodone | ✓ | | | |
| PB4ZHV | Oxycodone | | 140 | 40 | ng/mL |
| R2PQAR | oxycodone | ✓ | | | |
| R4GR9N | Oxycodone | | 0.11 ug/mL | +/-0.02 | ug/mL |
| RA2RQM | Oxycodone | | 0.12 | +/- 0.02 | ug/mL |
| RNNZNN | Oxycodone | ✓ | | | |
| T7FKJY | Oxycodone | | 146 | | ng/mL |
| TC3B7U | Oxycodone | ✓ | | | |
| TD3DVX | Oxycodone | | 124 | | ng/ml |
| TTCYGA | Oxycodone | ✓ | | | |
| U9HM6U | Oxycodone | ✓ | | | |
| UV969K | Oxycodone | ✓ | | | |
| UVBV6 | Oxycodone | ✓ | | | |
| UXY93R | oxycodone | ✓ | | | |
| UYA7X | Oxycodone | ✓ | | | |
| V4LDER | Oxycodone | | 0.16 | +/- 0.03 | ug/ml |
| VH3E8C | oxycodone | | 200 | | ng/mL |
| VKUATK | Oxycodone | | 149 | 29 | ng/ml |
| VMDMCM | Oxycodone | ✓ | | | |
| VNVBXN | Oxycodone | ✓ | | | |
| W34NNK | Oxycodone | | 0.12 | +/- 0.02 | ug/ml |
| WFW7GR | Oxycodone | | 0.10 | +/- 0.02 | ug/mL |
| WYNJPP | Oxycodone | | 116 | 26% | ng/mL |
| | Noroxycodone | | 28 | 29% | ng/mL |
| XBDFRN | oxycodone | | 0.13 mg/L | 0.03 | mg/L |

TABLE 3B Item 3

| Webcode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---------|---------------------------------|------------------|------------------------|-------------|-------|
| XMQWYK | oxycodone | | 0.14 | +/-0.04 | mg/L |
| YC9F9Y | **No drugs/metabolites detected | | | | |
| YXL4WP | Oxycodone | | >250.0 | | ng/mL |

| Response Summary for Item 3 | | Participants: 102 |
|--|-----|-------------------|
| Oxycodone: | 100 | |
| Noroxycodone: | 6 | |
| No drugs/metabolites detected: | 1 | |
| Other: | 1 | |
| <p>Totals may add up to more than the total number of participants because participants can report multiple drugs/metabolites.</p> | | |

Raw Data - Item 3

List of raw data determinations in ng/mL.

TABLE 3C Item 3
Item 3 Raw Data - Oxycodone
Preparation concentration: (150 ng/mL)

| Webcode | Raw Data (ng/mL) | | Participant Mean |
|---------|------------------|-------|------------------|
| 3RPK4H | 181.3 | | 181.3 |
| 46BFXM | 152.0 | | 152.0 |
| 4C8ATZ | 142.0 | 150.0 | 146.0 |
| 4DHARF | 128.0 | | 128.0 |
| 6DZMTX | 149.8 | | 149.8 |
| 7AD6BC | 118.0 | | 118.0 |
| 7ATPXV | 126.1 | | 126.1 |
| 7AVDZ8 | 139.7 | | 139.7 |
| 7FH2YJ | 150.0 | | 150.0 |
| 7FJ2UC | 144.9 | | 144.9 |
| 83RPZE | 131.0 | 118.0 | 124.5 |
| 8NAYYQ | 141.7 | | 141.7 |
| 8T34RV | 130.9 | | 130.9 |
| 9F8CHB | 146.0 | | 146.0 |
| 9KNGG7 | 106.0 | | 106.0 |
| ABG2BX | 118.0 | 121.0 | 119.5 |
| ALFUG4 | 141.2 | | 141.2 |
| AN7YEG | 176.8 | 175.8 | 176.3 |
| B2MB6G | 171.5 | 171.7 | 153.7 |
| BGE937 | 135.0 | | 135.0 |
| BHAUVW | 153.8 | 140.5 | 147.2 |
| BKW9K8 | 141.0 | | 141.0 |
| BX2N9N | 165.0 | | 165.0 |
| C2JBF2 | 147.0 | | 147.0 |
| CMHCT6 | 111.0 | | 111.0 |
| CQGQD9 | 134.9 | | 134.9 |
| DHM6M2 | 125.0 | | 125.0 |
| DPKU9C | 131.0 | | 131.0 |

TABLE 3C Item 3
Item 3 Raw Data - Oxycodone
Preparation concentration: (150 ng/mL)

| Webcode | Raw Data (ng/mL) | | | | Participant Mean |
|---------|------------------|-------|-------|-------|------------------|
| EJQEWA | 145.0 | | | | 145.0 |
| FMTHH6 | 108.3 | | | | 108.3 |
| FWT6A2 | 109.0 | | | | 109.0 |
| FZU93A | 134.0 | | | | 134.0 |
| HEPCGY | 113.0 | | | | 113.0 |
| HGDJ63 | 138.5 | | | | 138.5 |
| J7TW97 | 137.0 | | | | 137.0 |
| JD9D32 | 170.0 | | | | 170.0 |
| JNRR2X | 143.0 | | | | 143.0 |
| K6A8M6 | 154.0 | | | | 154.0 |
| KXQ83L | 127.9 | 127.5 | 134.7 | 134.0 | 131.0 |
| L67AMT | 148.0 | | | | 148.0 |
| LZEXPC | 159.0 | | | | 159.0 |
| M6MNIQW | 133.3 | | | | 133.3 |
| N628BU | 104.0 | | | | 104.0 |
| N7E2QU | 87.10 | 111.3 | | | 99.21 |
| N87Z6T | 104.0 | | | | 104.0 |
| NJ37XQ | 153.0 | 158.5 | | | 155.8 |
| PB4ZHV | 136.2 | | | | 136.2 |
| R4GR9N | 118.0 | | | | 118.0 |
| RA2RQM | 120.0 | | | | 120.0 |
| T7FKJY | 147.8 | 144.5 | | | 146.1 |
| TD3DVX | 130.6 | 118.6 | | | 124.6 |
| V4LDER | 160.0 | | | | 160.0 |
| VH3E8C | 200.0 | | | | 200.0 X |
| VKUATK | 149.0 | | | | 149.0 |
| W34NNK | 122.0 | | | | 122.0 |
| WFW7GR | 104.0 | | | | 104.0 |
| WYNJPP | 116.0 | | | | 116.0 |
| XBDFRN | 134.8 | | | | 134.8 |
| XMQWYK | 143.2 | | | | 143.2 |

TABLE 3C Item 3
Item 3 Raw Data - Oxycodone
Preparation concentration: (150 ng/mL)

| Webcode | Raw Data (ng/mL) | Participant Mean | |
|---------|------------------|------------------|---|
| YXL4WP | 273.8 | 273.8 | X |

| Statistical Analysis for Item 3 - Oxycodone | | | |
|---|--------------|--|-----------|
| Grand Mean | 135.9 | Number of Participants Included | 58 |
| Standard Deviation | 19.02 | Number of Participants Excluded | 2 |
| | | Number of Participants without Raw Data or Data that was not reported in ng/mL | 40 |

TABLE 3C Item 3

Item 3 Raw Data - Noroxycodone
Preparation concentration: (35 ng/mL)

| Webcode | Raw Data (ng/mL) | | Participant Mean |
|----------------|-------------------------|-------|-------------------------|
| NJ37XQ | 42.55 | 40.85 | 41.70 |
| WYNJPP | 28.00 | | 28.00 |

Statistical Analysis for Item 3 - Noroxycodone

Please note statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 3

If quantitative analysis was performed, the reported concentrations are:

TABLE 3D Item 3

| WebCode | Quantitative Reporting Procedures |
|---------|---|
| 2RDN2X | A single determination. |
| 3RPK4H | A single determination. |
| 46BFXM | A single determination. |
| 4C8ATZ | The mean of duplicate/several determinations. |
| 4DHARF | A single determination. |
| 6DZMTX | A single determination. |
| 7AD6BC | A single determination. |
| 7ATPXV | A single determination. |
| 7AVDZ8 | A single determination. |
| 7FH2YJ | A single determination. |
| 7FJ2UC | A single determination. |
| 8NAYYQ | A single determination. |
| 8T34RV | A single determination. |
| 9F8CHB | A single determination. |
| 9KNGG7 | A single determination. |
| ABG2BX | The mean of duplicate/several determinations. |
| ALFUG4 | A single determination. |
| AN7YEG | The mean of duplicate/several determinations. |
| BGE937 | A single determination. |
| BKW9K8 | A single determination. |
| BX2N9N | A single determination. |
| C2JBF2 | A single determination. |
| CMHCT6 | A single determination. |
| CQGQD9 | A single determination. |
| DHM6M2 | A single determination. |
| DPKU9C | A single determination. |
| EJQEWA | A single determination. |

TABLE 3D Item 3

| WebCode | Quantitative Reporting Procedures |
|----------------|---|
| FMTHH6 | A single determination. |
| FWT6A2 | A single determination. |
| FZU93A | A single determination. |
| HEPCGY | A single determination. |
| HGDJ63 | The mean of duplicate/several determinations. |
| J7TW97 | A single determination. |
| JD9D32 | A single determination. |
| JNRR2X | A single determination. |
| K6A8M6 | A single determination. |
| KXQ83L | The mean of duplicate/several determinations. |
| L67AMT | A single determination. |
| LZEXPC | A single determination. |
| M6MNQW | A single determination. |
| N628BU | A single determination. |
| N7E2QU | The mean of duplicate/several determinations. |
| N87Z6T | A single determination. |
| NJ37XQ | The mean of duplicate/several determinations. |
| PB4ZHV | A single determination. |
| R4GR9N | A single determination. |
| RA2RQM | A single determination. |
| T7FKJY | The mean of duplicate/several determinations. |
| TD3DVX | The mean of duplicate/several determinations. |
| V4LDER | A single determination. |
| VH3E8C | A single determination. |
| VKUATK | A single determination. |
| W34NNK | A single determination. |
| WFW7GR | A single determination. |
| WYNJPP | A single determination. |
| XBDFRN | A single determination. |
| XMQWYK | A single determination. |

TABLE 3D Item 3

| WebCode | Quantitative Reporting Procedures |
|---------|-----------------------------------|
| YC9F9Y | A single determination. |
| YXL4WP | A single determination. |

| Response Summary for Item 3 | Participants: 59 |
|---|------------------|
| A single determination: | 50 (84.7%) |
| The mean of duplicate/several determinations: | 9 (15.3%) |

Method of Analysis - Item 3

TABLE 3E Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---------|---|-------------|--------------|--------------|
| 2DPLGK | Immunoassay GC/MS | ✓ | ✓ | |
| 2RDN2X | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | |
| 3RPK4H | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | ✓ |
| 43M3WW | Immunoassay GC/MS | ✓ | ✓ | |
| 46BFXM | Immunoassay GC/MS LC/MS | ✓ ✓ | ✓ | ✓ |
| 4C8ATZ | Immunoassay LC/MS/MS UPLC QTOF MS | ✓ ✓ | ✓ | ✓ |
| 4DHARF | Immunoassay GC/MS | ✓ | ✓ | ✓ |
| 4ZHB6H | Immunoassay GC/MS | ✓ ✓ | ✓ | |
| 6DZMTX | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| 6FM2LE | Immunoassay GC/MS GC/NPD | ✓ ✓ ✓ | ✓ | |
| 7AD6BC | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| 7ATPXV | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| 7AVDZ8 | Immunoassay LC/MS/MS | ✓ | ✓ | ✓ |
| 7FH2YJ | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |
| 7FJ2UC | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| 7QGWE | Immunoassay GC/MS | ✓ | ✓ | |
| 7ZUQCG | Immunoassay GC/MS | ✓ | ✓ | |

TABLE 3E Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| 83RPZE | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| | LC-TOF | ✓ | | |
| 8NAYYQ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| 8T34RV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 8WMTC9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9833FR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9A48TC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9ANN9F | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9F8CHB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | | |
| 9JVLUX | Immunoassay | ✓ | | |
| 9KNGG7 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | | ✓ |
| 9LKREU | Immunoassay | ✓ | | |
| ABG2BX | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| | LC-QTOF | ✓ | ✓ | |
| | HPLC-DAD | ✓ | | |
| AHDRV9 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| ALFUG4 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| AN7YEG | LC/MS/MS | ✓ | ✓ | ✓ |
| AQCJ2G | GC/MS | ✓ | | |
| AYHL39 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| B2MB2B | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| B2MB6G | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS | | | ✓ |
| BBDW79 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| BF499W | Immunoassay | ✓ | | |

TABLE 3E Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---------|----------------------------------|-----------|--------------|--------------|
| BGE937 | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |
| BHAUVW | Immunoassay GC/MS | ✓ | ✓ | ✓ |
| BKW9K8 | Immunoassay GC/MS CG/FID | ✓ | ✓ ✓ | ✓ |
| BM3VXB | Immunoassay GC/MS | ✓ | ✓ | |
| BX2N9N | Immunoassay LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| C2JBF2 | Immunoassay LC/MS/MS | ✓ | ✓ | ✓ |
| CKVX4U | Immunoassay | ✓ | | |
| CMHCT6 | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| CQGQD9 | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| DAVJLA | GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | |
| DHM6M2 | Immunoassay GC/MS GC-FID | ✓ | ✓ ✓ | |
| DPKU9C | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |
| EJQEWA | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |
| EQXLY8 | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | |
| EV6CW8 | Immunoassay GC/MS | ✓ | ✓ | |
| F77W47 | Immunoassay GC/MS | ✓ | ✓ | |
| FHXQA8 | Immunoassay GC/MS | ✓ ✓ | ✓ | |
| FMTHH6 | Immunoassay LC/MS/MS | ✓ | ✓ | ✓ |
| FWT6A2 | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |

TABLE 3E Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---------|--|-------------|--------------|--------------|
| FZU93A | Immunoassay GC/MS GC-FID | ✓ | ✓ | ✓ |
| GGJE9H | Immunoassay GC/MS | ✓ | ✓ | |
| GX72E7 | LC/MS/MS | ✓ | ✓ | |
| H9ZU49 | LC/MS/MS | ✓ | | |
| HEPCGY | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | |
| HGDJ63 | LC/MS LC/MS/MS | ✓ | ✓ | ✓ |
| HZ9EF6 | Immunoassay GC/MS | ✓ | ✓ | |
| J6E88E | Immunoassay | ✓ | | |
| J7TW97 | Immunoassay GC/MS | ✓ | ✓ | ✓ |
| J7UKXW | Immunoassay GC/MS LC/MS | ✓ | ✓ ✓ | |
| JD9D32 | GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | ✓ |
| JNRR2X | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| K6A8M6 | Immunoassay GC/MS GC-FID | ✓ | ✓ | ✓ |
| KL6674 | Immunoassay | ✓ | | |
| KXE9AX | LC/MS/MS | ✓ | | |
| KXQ83L | Immunoassay GC/MS LC/MS/MS QTOF | ✓ ✓ ✓ | ✓ | ✓ ✓ |
| L67AMT | Immunoassay LC/MS/MS | ✓ | ✓ | ✓ |
| L68ZVW | Immunoassay GC/MS | ✓ | ✓ | |
| LZEXPC | Immunoassay LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| M6MNQW | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | |
| MVZKKH | Immunoassay | ✓ | | |
| MW9UE2 | Immunoassay GC/MS | ✓ | ✓ | |

TABLE 3E Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---------|----------------------------------|-------------|--------------|--------------|
| N628BU | Immunoassay GC/MS GC-FID | ✓ | ✓ | ✓ |
| N7E2QU | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ ✓ | ✓ |
| N87Z6T | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| NJ37XQ | Immunoassay GC/MS LC/MS/MS | ✓ ✓ | ✓ | ✓ |
| PATW9D | GC/MS LC/MS/MS | ✓ | ✓ | |
| PB4ZHV | Immunoassay GC/MS LC/MS/MS | ✓ ✓ ✓ | ✓ | ✓ |
| R2PQAR | Immunoassay GC/MS | ✓ | ✓ | |
| R4GR9N | Immunoassay GC/MS GC/FID | ✓ | ✓ | ✓ |
| RA2RQM | Immunoassay GC/MS GC/FID | ✓ | ✓ ✓ | ✓ |
| RNNZNN | Immunoassay GC/MS | ✓ | ✓ | |
| RUNGZE | Immunoassay | ✓ | | |
| T23MAQ | Immunoassay | ✓ | | |
| T7FKJY | Immunoassay GC/MS LC/MS/MS | ✓ | ✓ | ✓ |
| TC3B7U | Immunoassay GC/MS | ✓ | ✓ | |
| TD3DVX | Immunoassay GC/MS LC/MS/MS | ✓ | ✓ | ✓ |
| TTCYGA | LC/MS/MS | ✓ | ✓ | |
| U9HM6U | Immunoassay GC/MS | ✓ | ✓ | |
| UV969K | Immunoassay GC/MS | ✓ | ✓ | |
| UWBV6 | Immunoassay GC/MS | ✓ | ✓ | |
| UXY93R | Immunoassay GC/MS | ✓ | ✓ | |

TABLE 3E Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---------|-------------|-----------|--------------|--------------|
| UYA7X | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| V4LDER | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | | ✓ |
| VH3E8C | LC/MS/MS | ✓ | | ✓ |
| VKUATK | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | ✓ | | |
| VMDMCM | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| VNVBXN | LC/MS/MS | ✓ | ✓ | |
| W34NNK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC-FID | | | ✓ |
| WFW7GR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | GC/FID | | ✓ | ✓ |
| WYNJPP | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| XBDFRN | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | | |
| XMQWYK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | ✓ | | |
| YC9F9Y | LC/MS/MS | ✓ | ✓ | ✓ |
| YXL4WP | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |

| Response Summary for Item 3 | | Participants: 112 | | |
|-----------------------------|--|-------------------|--------------|--------------|
| | | Screening | Confirmatory | Quantitation |
| Immunoassay: | | 96 | 0 | 0 |
| GC/MS: | | 22 | 75 | 15 |
| LC/MS: | | 1 | 1 | 3 |
| LC/MS/MS: | | 23 | 29 | 21 |
| Other: | | 8 | 10 | 19 |

Additional Comments for Item 3

TABLE 3F Item 3

| WebCode | Item 3 - Comments |
|---------|---|
| 2DPLGK | Noroxycodone indications, weak mass spectrum, not reported |
| 2RDN2X | The quantitative value for Oxycodone in this proficiency sample was above our upper limit of quantitation. Therefore, the result was reported out qualitatively. |
| 4C8ATZ | Screening: Instrument: UPLC-QTOF MS (Waters). Salting-out assisted extraction. Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone. Oxycodone Quantitative Analysis: Instrument: UPLC-TQD (Waters). Internal Standard: D3-Oxycodone. LOD: 2 ng/mL |
| 4DHARF | Internal standards used were D6-Codeine, D6-Morphine, D3-Hydrocodone, D3-Hydromorphone, D6-Oxycodone, and D3-Oxymorphone. Limit of detection is 25 ng/mL. |
| 6DZMTX | oxycodone internal standard = oxycodone-d6; LOQ = 10 ng/mL |
| 79YZEZ | Immunoassay analyte: cutoff - Amphetamine: 20 ng/mL, Methamphetamine: 20 ng/mL, Morphine 20 ng/mL, Benzoylcegonine: 50 ng/mL, Oxazepam 50 ng/mL, Carboxytetrahydrocannabinol: 20 ng/mL |
| 7AD6BC | IS = Mepivacaine. LOQ = 0.05 ug/mL |
| 7ATPXV | oxycodone internal standard = oxycodone-d6; LOQ = 10 ng/mL |
| 7AVDZ8 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone, phencyclidine, and zolpidem. Confirmation/quantitation for oxycodone and oxymorphone following positive oxycodone screen. Oxycodone-D3 and oxymorphone-D3 used as internal standards. LOQ/LOD is 5 ng/mL for both oxycodone and oxymorphone. Oxymorphone was not detected. Confirmation/quantitation for amphetamine following positive screen. Amphetamine-D5 used as internal standard. LOQ/LOD is 4 ng/mL for amphetamine. Amphetamine was not detected. |
| 7FJ2UC | nalorphine |
| 7QGWE | Internal Standard: Mepivacaine |
| 7ZUQCG | Internal standards used: Mepivacaine, Nalorphine; Zolpidem indicated: not reported, immunoassay not indicative |
| 83RPZE | Internal standard: Oxycodone-D6. LOD: 12.5 ng/mL. LOQ: 25 ng/mL |
| 8T34RV | oxycodone internal standard = oxycodone-d6; LOQ = 10 ng/mL |
| 8WMTC9 | Mepivacaine used as an internal standard in the detection of Oxycodone. |
| 9A48TC | Cocaine related peaks indicated, immunoassay not indicative, no RRT to compare to, not reported. Zolpidem indicated, may be an artifact from production, not reported. |
| 9F8CHB | The internal standard used to quantitate oxycodone is butylated nalorphine. The limit of detection is 6.2 mcg/L for oxycodone. |
| AHDRV9 | Butyl Acetate Screen - Promazine (IStd), Opiate Confirmation - Nalorphine (IStd) |
| ALFUG4 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone. Oxycodone-D3 used as the internal standard. LOQ/LOD is 5 ng/mL for oxycodone. |

TABLE 3F Item 3

| WebCode | Item 3 - Comments |
|---------|--|
| BGE937 | Presumptive testing indicates the possibility of additional opiates. |
| BKW9K8 | IS= Mepivacaine. LOQ= 0.05 ug/mL. U of M= 17.74% at 95.45% (see calculated range above [Table 3B - Confirmatory Results-Item 3]) |
| BM3VXB | Internal standard: Mepivacaine |
| BX2N9N | Internal standard is Oxycodone-D6, Limit of detection is 10ng/mL |
| C2JBF2 | ELISA screening panel includes: amphetamine, benzodiazepines, cannabinoids, carisoprodol, cocaine and metabolites, methadone, opiates, oxycodone, phencyclidine, and zolpidem. Oxycodone-D3 used as internal standard. LOD/LOQ for oxycodone is 5ng/ml. |
| CKVX4U | The sample was screened for the following type/class of drugs: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, PCP |
| CQGQD9 | Internal standard- nalorphine |
| EJQEWA | Presumptive screen indicates the possibility of additional opiates. |
| EQXLY8 | OXYCODONE CONFIRMATORY limit of detection 50ng/mL(GC/MS , LC/MS/MS) |
| EV6CW8 | Internal Standard: Mepivacaine |
| F77W47 | Internal Standard used: Mepivacaine. Oxycodone Limit of Detection: 50 ng/mL. Zolpidem indicated but not confirmed due to Immunoassay screening negative for Zolpidem |
| FHXQA8 | Caffeine and ibuprofen were also confirmed in the blood sample. The drugs were not reported independently in sections 3-1 [Table 3A - Screening Results-Item 3] and 3-2 [Table 3B - Confirmatory Results-Item 3] because they were confirmed in more than one of the PT samples. |
| FWT6A2 | Expanded uncertainty 95.42%, K=2 (Oxycodone 17.74%) |
| HEPCGY | expanded uncertainty - 95.42%, k=2 (17.74) |
| HGDJ63 | Internal Standard = Estazolam (1000 ng/mL) |
| HZ9EF6 | GC/MS Internal Standard: Mepivacaine |
| JD9D32 | LOD (GC/MS) = 62.5 ng/mL, LOD (LC/MS/MS) = 25 ng/mL, Internal Standard (GC/MS) = Nalorphine, Internal Standard (LC/MS/MS) = Flurazepam |
| JNRR2X | Internal standard used is mepivacaine. LOQ is 0.05ug/ml. Measurement of certainty for oxycodone is calculated at 17.74% certainty at a 95.45% confidence level. Please see above for the calculated range [Table 3B - Confirmatory Results-Item 3]. |
| KL6674 | Cutoff concentration for oxycodone assay: 10 ng/mL |
| KXE9AX | Internal Standard = Estazolam |
| L67AMT | Internal Standard: d6-Oxycodone. LOD: 10 ng/mL. LOQ: 10 ng/mL |
| L68ZVW | The major ions of oxymorphone were observed; however, the concentration of oxymorphone in the sample was not sufficient to confirm by GCMS. |
| LZEXPC | Internal standard is Oxycodone-D6, Limit of detection is 10 ng/mL |
| M6MNQW | IS: mepivacaine. LOD: 6.2 µg/L |

TABLE 3F Item 3

| WebCode | Item 3 - Comments |
|---------|---|
| MVZKHH | Our immunoassay screening (ELISA) panel includes Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates and Phencyclidine. |
| N7E2QU | nalorphine used as internal standard. |
| NJ37XQ | LOQ for both analytes 10 ng/mL. Internal standard Oxycodone-D3 |
| PATW9D | Used Internal standards: For the screening: Phenobarbital D-5; For the Confirmatory: Codeine D-3 |
| PB4ZHV | Internal standard used: nalorphine |
| R4GR9N | I.S. = mepivacaine. Measurement uncertainty based on 17.74% at a 95.45% confidence interval |
| RNNZNN | Internal standard: Mepivacaine. Oxycodone LOD: 50 ng/ml. Noroxycodone and Zolpidem were indicated but not reported. |
| RUNGZE | Screen for following w/ cutt-off values: Amp 20ng/ml, Oxa 50ng/mL, BE 50ng/ml, Meth 20ng/ml, Morphine 20ng/ml, C-THC 20ng/ml. |
| T23MAQ | [From Table 3B - Confirmatory Results-Item 3: "No validated method available at this time."] |
| TC3B7U | Internal Standard: Mepivacaine; Zolpidem had a baseline indication but was not reported. |
| U9HM6U | Internal Standard - D6-Oxycodone @ 100 ng/mL (SIM) |
| UV969K | Internal Standard: Mepivacaine. Oxycodone LOD: 50ng/mL |
| VH3E8C | oxycodone-d6 as internal standard. LOD <0.1 ng/mL |
| VKUATK | oxycodone - d3 |
| VMDMCM | Opiate confirmation utilized Nalorphine internal standard. Butyl Acetate utilized Promazine internal standard. |
| W34NNK | Additional opiates are possible. |
| XBDFRN | internal standards: mepivacaine, nalorphine |
| XMQWYK | Internal standard: mepivacaine, BZE-d8, nalorphine, zolpidem quanted <LOR |

Additional Test Comments

TABLE 4

| WebCode | Additional Comments |
|----------------|---|
| 4C8ATZ | All samples appeared to contain traces of Metformin and Ibuprofen. |
| 79YZEZ | Limits of quantitation for analytes - MDA: 20 ng/mL, MDMA: 20 ng/mL, Tetrahydrocannabinol: 2 ng/mL. Hydroxytetrahydrocannabinol: 5 ng/mL, Carboxytetrahydrocannabinol: 10 ng/mL |
| 9LKREU | Only screening testing is performed at this location. |
| FHXQA8 | Caffeine was confirmed in all three PT samples. Ibuprofen was confirmed in two of the three PT samples. |
| J6E88E | All the items were screened using immunoassay method (Biochip Array Technology). No confirmatory method was performed for the screened positive sample. |
| KLG674 | Screening performed using ELISA. |
| LZEXPC | Low levels of Gabapentin and Zolpidem were detected but below the labs cutoff for quantitation. |

Appendix: Data Sheet

Collaborative Testing Services ~ Forensic Testing Program

Test No. 17-5661: Blood Drug Analysis

DATA MUST BE RECEIVED BY September 11, 2017 TO BE INCLUDED IN THE REPORT

Participant Code:

WebCode:

Accreditation Release Statement

CTS submits external proficiency test data directly to ASCLD/LAB, ANAB, and A2LA. Please select one of the following statements to ensure your data is handled appropriately.

- This participant's data is intended for submission to ASCLD/LAB, ANAB, and/or A2LA. (Accreditation Release section on the last page must be completed and submitted.)
- This participant's data is **NOT** intended for submission to ASCLD/LAB, ANAB or A2LA.

Scenario:

Investigators have submitted two vials of blood from each of three separate cases for your analysis. Using your laboratory's procedures, analyze each item and report the presence of any drugs and/or metabolites.

Case 1: The body of a 52 year old female was found in her home. Her lips and extremities were blue, foam was present around her mouth, and a syringe was found nearby. A blood sample was collected at the autopsy.

Case 2: A 26 year old female was arrested at a party. The arresting officer noted that she exhibited sweating, chills, dilated pupils, and confusion. A blood sample was collected 80 minutes after the arrest.

Case 3: A 35 year old male was pulled over by police after running a red light. He displayed drowsiness, slurred speech, and confusion. A breath alcohol test resulted in 0.00 percent. A blood sample was collected 1 hour later.

Instructions:

****PLEASE NOTE**** The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly.

-Please do not report the presence/concentration of drugs in concentrations less than 10ng/mL.

-Samples may contain methanol, acetonitrile, Zolpidem, and Gabapentin as artifacts from production.

Items Submitted (Sample Pack BDRG):

Item 1: Two vials of blood from Case 1

Item 2: Two vials of blood from Case 2

Item 3: Two vials of blood from Case 3

Please return all pages of this data sheet.

Page 1 of 9

Participant Code:

WebCode:

Screening Results for Item 1:

1-1.) Please indicate the screening results for Item 1

- No drugs detected utilizing screening methods.
- Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 1:

1-2.) What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

The number of boxes shown does not indicate the number of analytes present. If additional space is needed, copy this page or attach your own form following this layout.

- No drugs/metabolites detected utilizing confirmatory methods.

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

Please return all pages of this data sheet.

Participant Code:

WebCode:

Results for Item 1 (continued):

1-3.) If quantitative analysis was performed, are the reported concentrations for Item 1:

- A single determination? The mean of duplicate / several determinations?
- Other? (Specify): _____

1-4.) Please check the methods used to analyze Item 1 by selecting whether each method used was for screening, confirmatory testing and/or quantitation.

| <u>Method Used</u> | <u>Screening</u> | <u>Confirmatory</u> | <u>Quantitation</u> |
|--------------------|--------------------------|--------------------------|--------------------------|
| Immunoassay | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| GC/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| LC/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| LC/MS/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Other: _____ | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Other: _____ | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

1-5.) Additional Comments for Item 1

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please return all pages of this data sheet.

Participant Code:

WebCode:

Screening Results for Item 2:

2-1.) Please indicate the screening results for Item 2

- No drugs detected utilizing screening methods.
- Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 2:

2-2.) What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

The number of boxes shown does not indicate the number of analytes present. If additional space is needed, copy this page or attach your own form following this layout.

- No drugs/metabolites detected utilizing confirmatory methods.

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

Please return all pages of this data sheet.

Participant Code:

WebCode:

Results for Item 2 (continued):

2-3.) If quantitative analysis was performed, are the reported concentrations for Item 2:

- A single determination? The mean of duplicate / several determinations?
- Other? (Specify): _____

2-4.) Please check the methods used to analyze Item 2 by selecting whether each method used was for screening, confirmatory testing and/or quantitation.

| <u>Method Used</u> | <u>Screening</u> | <u>Confirmatory</u> | <u>Quantitation</u> |
|--------------------|--------------------------|--------------------------|--------------------------|
| Immunoassay | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| GC/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| LC/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| LC/MS/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Other: _____ | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Other: _____ | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

2-5.) Additional Comments for Item 2

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please return all pages of this data sheet.

Participant Code:

WebCode:

Screening Results for Item 3:

3-1.) Please indicate the screening results for Item 3

- No drugs detected utilizing screening methods.
- Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 3:

3-2.) What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

The number of boxes shown does not indicate the number of analytes present. If additional space is needed, copy this page or attach your own form following this layout.

- No drugs/metabolites detected utilizing confirmatory methods.

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|--|--------------------------|------------------------|-------------|-----------|
| _____ | <input type="checkbox"/> | _____ | _____ | (_____) |
| Date(s) Analysis Performed on Analyte: _____ | | | | |
| Raw Data (ng/mL): | | | | |
| _____ | _____ | _____ | _____ | _____ |

Please return all pages of this data sheet.

Participant Code:

WebCode:

Results for Item 3 (continued):

3-3.) If quantitative analysis was performed, are the reported concentrations for Item 3:

- A single determination? The mean of duplicate / several determinations?
- Other? (Specify): _____

3-4.) Please check the methods used to analyze Item 3 by selecting whether each method used was for screening, confirmatory testing and/or quantitation.

| <u>Method Used</u> | <u>Screening</u> | <u>Confirmatory</u> | <u>Quantitation</u> |
|--------------------|--------------------------|--------------------------|--------------------------|
| Immunoassay | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| GC/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| LC/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| LC/MS/MS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Other: _____ | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Other: _____ | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

3-5.) Additional Comments for Item 3

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please return all pages of this data sheet.

Participant Code:

WebCode:

Date Samples Received: _____

Additional Comments on Test

| | |
|---|---|
| <p><u>Return Instructions:</u> Data must be received via online data entry, fax (please include a cover sheet), or mail by <i>September 11, 2017</i> to be included in the report. Emailed data sheets are not accepted.</p> <p>QUESTION? TEL: +1-571-434-1925 (8 am - 4:30 pm EST) EMAIL: forensics@cts-interlab.com www.ctsforensics.com</p> | <p>Participant Code: ONLINE DATA ENTRY: www.cts-portal.com</p> <p>FAX: +1-571-434-1937</p> <p>MAIL: Collaborative Testing Services, Inc. P.O. Box 650820 Sterling, VA 20165-0820 USA</p> |
|---|---|

Please return all pages of this data sheet.

Collaborative Testing Services ~ Forensic Testing Program

RELEASE OF DATA TO ACCREDITATION BODIES

The following Accreditation Releases will apply only to:

Participant Code:

WebCode:

for Test No. **17-5661: Blood Drug Analysis**

This release page must be completed and received by **September 11, 2017** to have this participant's submitted data included in the reports forwarded to the respective Accreditation Bodies.

Have the laboratory's designated individual complete the following steps **only if your laboratory is accredited in this testing/calibration discipline** by one or more of the following Accreditation Bodies.

Step 1: Provide the applicable Accreditation Certificate Number(s) for your laboratory

ASCLD/LAB Certificate No. _____

ANAB Certificate No. _____

A2LA Certificate No. _____

Step 2: Complete the Laboratory Identifying Information in its entirety

Signature and Title _____

Laboratory Name _____

Location (City/State) _____

| | |
|---|--|
| Accreditation Release | |
| Return Instructions | |
| <i>Please submit the completed Accreditation Release at the same time as your full data sheet. See Data Sheet Return Instructions on the previous page.</i> | <i>Questions? Contact us 8 am-4:30 pm EST Telephone: +1-571-434-1925 email: forensics@cts-interlab.com</i> |

Please return all pages of this data sheet.